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RESEARCH SUMMARY 
 
 
 
Even though transporters that extrude toxic compounds are found in all types 
of cells, they vary in the chemical diversity of their transported substrates, in their 
molecular architecture and in their energization source. In Gram-negative bacteria, 
drug transporters belonging to the resistance-nodulation-cell division (RND) family of 
proteins are especially abundant. A common feature of these RND-transporters is 
their utilization of the proton electrochemical gradient to energize the transport of 
substrates and that they transport a variety of chemically diverse substances. Among 
them are also several antibiotic agents, which often leads to clinically relevant 
multidrug resistance in bacteria. These multidrug-resistant bacteria represent a rising 
problem in the treatment of bacterial infections nowadays. 
 
This doctoral thesis focused on the structural biology of members of the RND-
transporter family. At the beginning of this thesis the X-ray crystal structure of one 
family member, Escherichia coli AcrB, was known at 3.5 Å resolution and revealed 
the general architecture of this family of proteins. Little was known, however, at the 
structural level, about how these transporters accomodate and translocate such a 
diversity of substrates. Our goal was therefore to gain further insight into the 
molecular mechanism of multidrug transport. As integral membrane proteins are 
notoriously difficult to crystallize, we made use of the designed ankyrin repeat protein 
(DARPin) technology to improve their crystallization behaviour. DARPins are built 
based on the natural ankyrin repeat protein fold onto which novel specificities were 
designed. A library consisting of a myriad of individual DARPin molecules was used in 
combination with the in vitro selection technique ribosome display, to select specific 
binders to several target transporters. 
 
The X-ray structure of Escherichia coli AcrB in complex with a selected 
inhibitory DARPin at 2.54 Å resolution revealed a novel asymmetric conformation of 
the RND-transporter, where each subunit of the trimeric protein adapted a slightly 
different conformation. This study revealed novel mechanistic details of drug 
transport. The DARPin approach hereby greatly facilitated the crystallization of AcrB 
by stabilizing the asymmetric conformation and improved the resolution significantly. 
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To add structural information and to learn more about multidrug transport of 
RND-transporters, the X-ray structure of Pseudomonas aeruginosa MexB was 
determined at 3.0 Å resolution. Despite the importance of this transporter considering 
the pathogenicity and resistance properties of P. aeruginosa, this structure was not 
known. This represents only the second structure of a protein of this family of drug 
transporters. Not surprisingly, given the high sequence homology between them, 
MexB adopted an asymmetric fold very similar to AcrB but showed prominent 
conformational changes in one subunit. Moreover a detergent molecule, deriving 
from the purification, was bound in one of the binding cavities. Together with a high-
resolution X-ray structure of AcrB in complex with its substrate minocycline we 
gained useful information on the detailed three-dimensional organization of the drug-
binding site and on the capability of multidrug transporter to exhibit such broad 
substrate specificity. Since RND-transporters are usually part of a multicomponent 
efflux system, the structures of single-components and hopefully also of whole three-
component systems in the future, will help to develop agents able to act as efflux 
inhibitors, thereby reviving the effectiveness of many efflux-affected antibiotics. 
Research Summary
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ZUSAMMENFASSUNG 
 
 
 
Transporterproteine, welche giftige Stoffe aus der Zelle transportieren, 
kommen zwar in allen Zelltypen vor, unterscheiden sich aber in der 
Verschiedenartigkeit der von ihnen transportierten Substanzen, in ihrer molekularen 
Architektur und ihrer Energiequelle. In Gram-negativen Bakterien findet man 
besonders häufig Transporter die zur sogenannten „resistance-nodulation-cell 
division“ (Widerstand-Knöllchenbildung-Zellteilungs, RND) Proteinfamilie gehören. 
Eine Gemeinsamkeit dieser RND-Transporter ist es, dass sie alle den 
elektrochemischen Protonengradienten als Energiequelle für den Transport von 
Stoffen nützen, und dass sie eine grosse Anzahl von chemisch sehr 
unterschiedlichen Substanzen transportieren. Unter diesen befinden sich auch einige 
antibiotisch wirkende Substanzen, was oft zur klinisch bedeutenden Resistenz 
gegenüber verschiedensten Medikamenten führt. Diese mehrfach resistenten 
Bakterien stellen gegenwärtig ein grosses Problem in der Behandlung von 
bakteriellen Infektionen dar. 
 
Diese Doktorarbeit konzentrierte sich auf die Strukturbiologie von Vertretern 
dieser RND-Transporter Familie. Zu Beginn dieser Arbeit war die 
Röntgenkristallstruktur von einem Familienmitglied, AcrB, bei einer Auflösung von 3.5 
Å bekannt und hat die generelle Architektur dieser Proteinfamilie aufgezeigt. Nur 
wenig war jedoch bekannt, wie genau diese Transporter eine solche Vielfalt an 
Substanzen aufnehmen und durchschleusen können. Unser Ziel war es deshalb 
weitere Einsichten in den molekularen Mechanismus dieses vielfältigen Transports 
zu gewinnen. Da in einer Membran sitzende Proteine bekanntermassen schwer zu 
kristallisieren sind, haben wir sogenannte massgeschneiderte Ankyrin Repeat 
Proteine (DARPins) benutzt, um ihre Kristallisationseigenschaften zu verbessern. 
DARPins gründen auf der Faltung von natürlichen Ankyrin Repeat Proteinen, auf 
welche neue Spezifitäten gebaut wurden. Eine Protein Bibliothek, bestehend aus 
unzähligen individuellen DARPin Molekülen, wurde zusammen mit der Technik 
„ribosome display“ verwendet, um spezifische Binder für mehrere Zieltransporter zu 
finden. 
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Bei einer Auflösung von 2.54 Å zeigte die Röntgenstruktur des Escherichia coli 
Proteins AcrB in einem Komplex mit einem gefundenen hemmenden DARPin eine 
neue asymmetrische Gestalt dieses RND-Transporters, in welcher jede Untereinheit 
des trimeren Proteins eine leicht andere Konformation einnahm. Diese Studie 
offenbarte neue mechanistische Details des Substanztransports. Durch die 
Stabilisierung der asymmetrischen Form mit dem Ansatz der DARPins wurde in 
diesem Falle die Kristallisation von AcrB beträchtlich vereinfacht und die Auflösung 
erheblich verbessert. 
 
Um weitere strukturelle Informationen und Erkenntnisse über den 
Substanztransport dieser RND-Transporter Familie zu gewinnen, wurde die 
Röntgenstruktur von Pseudomonas aeruginosa MexB, bei einer Auflösung von 3.0 Å 
gelöst. Diese Struktur war trotz der Wichtigkeit dieses Transporters in Bezug auf P. 
aeruginosa als Krankheitserreger und seine Resistenzeigenschaften, nicht bekannt. 
Sie ist daher erst die zweite Struktur dieser Proteinfamilie. MexB nimmt eine sehr 
ähnliche asymmetrische Form ein wie AcrB, was nicht erstaunt, wenn man die 
grosse Sequenzähnlichkeit der beiden bedenkt, aber MexB zeigt markante 
Änderungen in einer Untereinheit auf. Ausserdem ist ein Detergensmolekül aus der 
Reinigung in einer der Bindungstaschen gebunden. Zusammen mit einer 
hochaufgelösten Röntgenstruktur von AcrB mit gebundenem Substrat Minocyclin 
haben wir nützliche Erkenntnisse über das detaillierte dreidimensionale Aussehen 
der Substratbindungsstelle und über die Fähigkeit so viele verschiedene Stoffe zu 
transportieren, gewonnen. Weil RND-Transporter gewöhnlich Teil von 
Mehrkomponentsystemen sind, werden die Strukturen von Einzelkomponenten and 
hoffentlich in Zukunft auch die von ganzen Dreikomponentsystemen, in der 
Entwicklung von Stoffen helfen, welche den Transport hemmen können und so die 
Wirksamkeit von vielen vom Transport betroffenen Antibiotika wiederbeleben.  
Zusammenfassung
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CHAPTER 1 
 
BACTERIAL MULTIDRUG RESISTANCE 
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With the discovery of antibacterial drugs in the first half of the 20th century and the 
availability of a number of different antibiotic compounds in the 1980ties bacterial 
infections were considered no longer life-threatening and a lot of infectious diseases 
seemed to be eradicated. Nevertheless, almost as soon as these `magic bullets` 
were in use, bacterial strains evolved ways to overcome them. The excessive use of 
antibiotics has further increased the emergence of antibiotic-resistant pathogens. 
Particularly in hospitals, where various microbes can come in close contact with one 
another, resistance has been reported in many bacteria and often results in severe 
treatment failure. Furthermore, efflux-caused drug resistance is a medical problem 
not only restricted to bacterial infections, it is also arising in many tumours exhibiting 
resistance to anticancer therapy. 
 
1.1 Efflux as resistance mechanism to antibacterial drugs 
 
Resistance may occur as an intrinsic feature of an organism, or when it is not, 
the transfer of normally susceptible into resistant may be acquired either through 
mutation, or by obtaining the genetic information that encodes resistance from other 
bacteria. Generally, bacteria can resist the action of antibiotics through three 
strategies: inactivation of the antibiotic drug, alteration of the target protein, and 
reduced drug accumulation due to a decrease in membrane permeability and active 
efflux of the agent [1]. Clinically relevant levels of resistance can be explained, in 
many cases, by a synergy between these mechanisms. Multidrug resistance, 
however, defined as resistance of an organism to more then one class of antibiotics, 
is almost exclusively associated with the expression of drug exporters. Except a few 
examples where these genes are found on mobile elements, almost all multidrug 
transporters are chromosomally encoded [2]. 
 
The phenomenon of antibiotic efflux was first described in 1978 for transport 
proteins that expel tetracyclines from Escherichia coli [3]. Tetracycline transporters 
are specific, transporting only one given drug or class of drugs. In contrast, multidrug 
transporters are broad-specific, accomodating compounds with very diverse 
structures and cellular targets. In either case, specific or broad-specific, the effect of 
all these drug exporters is the extrusion of toxic substances from the cell before they 
can reach their site of action. Thereby the effective intracellular drug concentration is 
Chapter 1 - Bacterial Multidrug Resistance
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reduced and the susceptibility of a bacterial cell to an antibiotic agent can be 
decreased by several orders of magnitude. In combination with other resistance 
mechanisms this can lead to clinically relevant levels of antibiotic resistance. 
 
The natural physiological function of these bacterial drug exporters has been 
much debated in the literature and still is a widely discussed subject [4]. In antibiotic-
producing organisms, like the tetracycline-producing Streptomyces spp., the 
expression of such a protecting drug transporter is self-explanatory. From these 
organisms such genes could have been acquired then by other bacteria. The 
extrusion of exogenous toxic compounds produced by the host is another discussed 
intended function of multidrug transporters. The transport capability of substances 
such as bile salts and fatty acids by the AcrAB-TolC system from Enterobacteria and 
its homologs in other Gram-negative bacteria is a well known example to explain the 
survival of these organisms in high concentrations of these substances encountered 
in the gut of mammals. The expulsion of endogenous metabolites whose presence 
could be toxic above certain concentrations has also been discussed [5] and recently 
it was proposed that efflux pumps could play also a role in the pathogenicity of the 
bacterium, exporting virulence factors that are important for the colonization and 
infection of cells [4]. In these contexts, it seems that antibiotics are simply subject to 
efflux because they share the necessary basic structural features for efflux such as 
the presence of a relatively large hydrophobic part or the amphiphile character. 
 
1.2 Bacterial multidrug transporters 
 
Despite their individual differences, multidrug transporters share the ability to 
expel a wide variety of structurally diverse compounds. Bacterial multidrug 
transporters can be assigned to five larger classes of transporters, independent of 
their substrates [6]: the ATP-binding cassette (ABC) superfamily, the major facilitator 
superfamily (MFS), the multidrug and toxic-compound extrusion (MATE) family, the 
small multidrug resistance (SMR) family and the resistance-nodulation-cell division 
(RND) family (Fig. 1). Transporters within a superfamily are related with regard to 
primary/secondary structure and energization requirements. Multidrug transporters 
are found in virtually all bacteria and often a single organism expresses transporters 
from more than one family and several types belonging to the same family.  
Chapter 1 - Bacterial Multidrug Resistance
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Fig. 1.  
Schematic illustration of the five classes of bacterial drug transporters. Shown are 
representative members of the corresponding families: Lactococcus lactis LmrA, Staphylococcus 
aureus NorA, Vibrio parahaemolyticus NorM, Escherichia coli EmrE, and Escherichia coli AcrB. The 
RND-transporter family is shown as multicomponent system, together with an outer membrane 
protein and a membrane fusion protein, representing their functional architecture in Gram-negative 
bacteria. Adapted from [7]. 
 
Most of the transporters function as secondary transporters using the 
transmembrane electrochemical gradient of ions to mediate drug export. The 
transporters belonging to the MF-, RND- and SMR-families are H+-driven, whereas 
those of the MATE-family are mostly Na+-driven. The exception is the ABC 
superfamily whose members derive their energy for transport through ATP-hydrolysis 
and are therefore primary transporters. Drug transporters of the ABC family are 
especially abundant in eukaryotic cells, where they confer resistance to 
chemotherapeutic drugs, but are not very common in bacteria. Classical drug 
transporters, such as the ones found in Gram-positive bacteria, consist of a single 
component with several transmembrane spanning domains. Especially abundant and 
clinically significant in Gram-positive bacteria are efflux pumps of the MF superfamily. 
More elaborate systems exist in Gram-negative bacteria, which have a much higher 
level of intrinsic resistance compared to the Gram-positive. The majority of multidrug 
transporters there is organized as multi-component systems, to ensure a complete 
removal of an agent across both membranes (Fig. 1). Although RND-transporters are 
not unique to Gram-negative bacteria [8], they are the most prominent in these 
organisms and most relevant in respect of intrinsic and acquired resistance to 
Chapter 1 - Bacterial Multidrug Resistance
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clinically significant antibiotics [9]. Most RND-transporters studied to date are 
multidrug transporters [5]. 
 
1.3 RND-transporter family 
 
RND-transporters are large proteins composed typically of around 1000 amino 
acid residues. They all display an unusual topology consisting of 12 transmembrane 
helices (TMs) with two large periplasmic loops between TM1 and 2 and TM7 and 8 
(Fig. 2). The N-terminal halves resemble the C-terminal halves and, as such, these 
proteins are believed to have arisen from an intragenic duplication event during 
evolution [10]. Reconstitution studies have confirmed that the RND-transporters are 
H+/substrate antiporters [11] and substitutions of three conserved charged residues in 
the transmembrane domain (Asp-407 and Asp-408 of TM4 and Lys-940 (AcrB) or 
Lys-939 (MexB) of TM10) led to a complete loss of transport activity, indicating a 
probable function in proton translocation [12].  
 
The determination of the structure of the E. coli RND-transporter AcrB in 2002 
was a major breakthrough [13]. It was not only the first structure of an RND-family 
member but also the first multidrug and the first proton coupled transporter. The 
overall structure was shown to be a trimer (Fig. 2A). Besides the 36-helix 
transmembrane domain, the periplasmic loops fold into two prominent domains 
parallel to the membrane, the adjacent pore domain and the docking domain, being 
40 Å and 30 Å thick respectively. Interestingly, the docking domain forms a funnel-
like opening, with an internal diameter of 30 Å which is connected by a pore to a 
large central cavity formed by the transmembrane domains of the subunits. Originally 
it was thought that this symmetric structure represents the closed structure of AcrB 
and substrates are transported upon opening of the pore in an “elevator-like” 
mechanism via this central pathway. The pore domain is further arranged into four 
subdomains, PN1, PN2, PC1, and PC2, each comprising two –motifs and the 
docking domain is composed of two subdomains, DN and DC (Fig. 2B). The whole 
trimer is held together by a hairpin structure formed by subdomain DN that protrudes 
from each subunit into the next subunit.  
 
Chapter 1 - Bacterial Multidrug Resistance
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Most RND-transporters promote resistance to a wide range of substrates. 
Nevertheless, the type and number of agents varies from organism to organism, even 
for pumps with a high degree of sequence homology. It is not clear whether these 
differences reflect the actual substrate specificity of these transporters. Variations in 
the intrinsic outer membrane permeability of the host organism and the presence of 
other drug transporters could compromise the drug resistance pattern of an 
organism. The best studied transporters, AcrB of E. coli and MexB of P. aeruginosa 
expel mostly lipophilic and amphiphilic compounds, many of them carrying either 
positive or negative or even both charges. One common feature of the majority of the 
substrates, however, appears to be a large hydrophobic framework. How a single 
protein can recognize such a variety of chemically unrelated compounds is an 
intriguing question and was a point that was not answered by the first AcrB structures 
[13-15]. Several studies showed that the periplasmic loops of RND transporters are 
critical for substrate recognition [16-18]. Recent advances in the structural analysis of 
AcrB, including the work that was done in the course of this thesis, and the structures 
of a number of soluble multidrug-recognizing proteins such as the regulator proteins 
which can bind a similar broad range of drugs showed how these substrates are 
recognized. The proteins possess large hydrophobic binding sites and bind their 
substrates through a combination of stacking, van der Waals and electrostatic 
interactions, rather than a specific network of hydrogen bonds and other specific 
interactions like in most enzymes and receptors. 
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Fig. 2.  
X-ray structure of the RND-transporter AcrB (1IWG). A Ribbon representation of the trimeric AcrB 
structure. The individual subunits are colored and the three main domains are labelled. B Topology 
diagram of AcrB with labelled subdomains. Adapted from [13]. 
 
1.4 Drug efflux in Gram-negative bacteria: 
 The formation of tripartite efflux pumps 
 
Gram-negative bacteria possess both a cytoplasmic and an outer membrane 
separated by the periplasmic space. As transport out of the cytoplasm only would be 
insufficient and as many antibiotic targets reside in the periplasm, like the cell wall 
components targeted by the -lactams, effective removal of antibiotics requires 
transport also across the outer membrane. The outer membrane however, unable to 
maintain an electrochemical gradient or to access ATP, needs the inner membrane 
as source of energy. As a consequence, RND-transporters as well as some MFS- 
(e.g. the EmrAB-TolC system of E. coli) and ABC-transporters (e.g. the HlyBD-TolC 
system of E. coli) expressed by Gram-negativ bacteria typically operate as 
multiprotein efflux systems consisting of a an energy-providing transporter located in 
the cytoplasmic membrane, a pore-like outer membrane protein (OMP) and a 
periplasmic protein connecting them (a membrane-fusion protein (MFP) family 
member). It is thought that substrates are captured by the transporter protein and 
then are transported out of the cell through the OMP, which forms a channel through 
the outer membrane [19]. The most extensively characterized RND tripartite systems 
are the E. coli AcrAB-TolC and the P. aeruginosa MexAB-OprM system. 
Chapter 1 - Bacterial Multidrug Resistance
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Many outer membrane components are multifunctional and can couple to 
different transporters located in the inner membrane, therefore their role in 
determining the specificity or directionality of transport seems not to be important. For 
example, TolC serves as general outer membrane channel in E. coli. It works 
together with different RND-transporters besides AcrB, and also with some MFS- and 
ABC-transporters. Similarly, OprM of P. aeruginosa can function with several RND-
transporters [20]. The genes for such a tripartite system are often organized in one 
operon, in which a regulator gene is located adjacent to the gene encoding the MFP, 
which is located adjacent to the gene enconding the transporter, which in turn is 
located next to the OMP gene. All components are usually cotranscribed. Some 
OMPs, however, such as TolC, are located on the chromosome distant from the 
other tripartite components. As TolC is the universal OMP component of tripartite 
systems in E. coli, it has to interact with diverse transporters and its regulation 
independent of the individual transporters is not surprising.  
 
The crystal structures of individual components of the two best characterized 
systems AcrAB-TolC and MexAB-OprM provided a structural basis to the current 
understanding of drug export through two membranes (see Chapters 3 and 4) (TolC 
[21], AcrB [13], MexA [22, 23], OprM [24], AcrA [25]). Nevertheless, the precise 
biochemical function, the specific association and the oligomeric state of the MFPs 
and therefore also the assembly of the whole tripartite system remains unknown and 
is discussed controversially. MFPs are fairly unifom in size (380-480 residues) [5] and 
are attached to the inner membrane by a single N-terminal transmembrane helix or 
by lipid modification of a conserved N-terminal cysteine residue after cleavage of the 
periplasmic signal sequence. However, the membrane attachment is not essential for 
drug efflux activity, since N-terminal mutants of the MFPs AcrA and MexA devoid of 
lipid modification, remained functional [26, 27].   
 
The similarity in size and symmetry between the periplasmic end of the OMP 
and the tip of the periplasmic domain of RND-transporter has prompted the 
suggestion that these domains could directly interact. In vivo cross-linking 
experiments have indeed shown a close proximity between the RND and OMP 
components of both major efflux systems AcrB and TolC [28, 29] and MexB and 
OprM [30, 31]. AcrA was further shown to form stable interactions with both AcrB and 
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TolC [28, 32]. An often applied strategy to gain insight into the relevant parts for the 
assembly is the adaptation of the two best characterized efflux pumps AcrAB-TolC 
and MexAB-OprM to each other [33, 34]. These studies all showed that the -helical 
hairpin of the MFPs interacts with the OMPs and the -barrel and lipoyl-domain 
interacts with the RND-component.  
 
 
 
Fig. 3.  
Models of the tripartite assembly. A MexA/MexB*-OprM [22] B MexA/MexB*-OprM [22] C 
MexA/AcrB-TolC [23] D AcrA*/AcrB-TolC [35]. *These structures derived from modeling on an 
available crystal structure of the homologous protein. 
 
Based on the individual protein structures and molecular interaction studies, 
several models of the complete pump assembly have been proposed (Fig. 3) [19, 22, 
23, 35]. They mainly differ in the oligomeric state and extend of the interaction of the 
MFP component. Akama et al. proposed two options: (i) a 12-mer sheath around 
both OprM and MexB similar to the oligomeric structure in the crystal and (ii) a 
threefold dimer model [22]. Higgins et al. proposed a model with nine monomers 
forming a sheath around OprM and MexB [23] and Fernandez-Recio et al. modelled 
an open conformation of TolC and predicted a subunit stoichiometry of 1:1:1 for the 
OMP:MFP:transporter components [35]. It is far from clear how these pumps 
assemble and if the MFPs simply stabilize the RND-OMP-complex or play a more 
active role in the transport event itself. But it seems that multidrug export systems are 
constitutively assembled independent of the presence of a substrate [28]. 
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1.5 Regulation of multidrug transporter expression 
 
A large number of studies have been undertaken to understand the complex 
regulation of efflux pump gene expression [36]. There are usually two ways how drug 
transporters are regulated, via local and global regulators (Fig. 4). Many pumps are 
controlled via repressors that are transcribed divergently to the efflux pump operon. 
The local repressor of the acrAB genes, AcrR belongs to the TetR repressor family 
[37], the one of the mexAB-oprM genes, MexR, to the MarR family [38]. These 
repress their own and the pump expression by binding to the promoter regions of the 
respective genes. In the case of AcrAB and MexAB-OprM the repression is generally 
loose, allowing constitutive expression of the proteins. Mutations in the repressor 
gene can fully inhibit the repression of the efflux pump gene and lead to 
overexpression of the latter.  
 
 
Fig. 4.  
Local and global regulation of the AcrAB-TolC tripartite system expression in E. coli. Adapted from 
[39]. 
 
The global regulation of the AcrAB-TolC system is the best characterized so 
far. But it is believed that the expression of MexAB-OprM is also controlled by global 
regulators. AcrAB-TolC is tightly regulated through at least four global activators: 
MarA, SoxS, Rob and SdiA. Often these global regulators control also the expression 
of outer membrane porins (Fig. 4), thereby emphasizing again the important synergy 
Chapter 1 - Bacterial Multidrug Resistance
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between different resistance mechanisms, here the active efflux and low outer 
membrane permeability.  
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CHAPTER 2 
 
MEMBRANE PROTEIN CRYSTALLIZATION 
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Membrane proteins, like the RND-transporters, are biological macromolecules that 
mediate diverse functions in all organisms by allowing molecules to pass a lipophilic 
membrane or to send a signal through it. Analysis of genomic data revealed that they 
account for between 25 and 30% of all encoded proteins [1]. Despite their significant 
abundance, high-resolution structures are available only for a limited number of this 
special class of proteins. Only 157 different membrane proteins have been 
characterized structurally whereas the number of all entries in the Protein Data Bank 
exceeded 50000. This low number reflects the difficulties encountered in structural 
biology with these challenging proteins.  
 
2.1 Problems and Solutions 
 
Atomic-resolution structures of membrane proteins are indispensable to 
understand their function. A prerequisite for the structural characterization of any 
biological macromolecule is the homogeneity of the sample in terms of purity, quality 
(secondary modifications or proteolytic cleavage) and conformational uniformity. 
Many recombinantly expressed and purified soluble proteins do not fulfill these 
requirements. The situation is even more complex for membrane proteins and even 
more difficulties arise. Apart from the ones mentioned above, membrane proteins are 
naturally embedded within the lipid bilayer of a cell or an organelle. Therefore they 
contain both a hydrophobic part buried within the lipids and a hydrophilic part 
exposed to the solvent. In order to purify such lipid embedded molecules it is 
beneficial to extract them from their environment since the lipid bilayer is very 
complex and not suitable for crystallization. The amphipathic nature of detergents is 
well suited to stand in for the lipids. They mimic the lipid bilayer by covering the 
hydrophobic part of the protein with their hydrophobic tail and simultaneously interact 
with the aequous environment via their polar head groups. These interactions 
prevent the aggregation of the hydrophobic region of a membrane protein. However, 
choosing the wrong detergent can have dramatic effects on a protein e.g. by partly 
denaturing it. A loss of stability or function is therefore an often encountered problem 
upon solubilization with a detergent. Choosing the right detergent, in contrast, can 
have a dramatic effect on the crystallization behaviour of a membrane protein and 
can be the key to successful crystallization.  
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The next step towards the structural characterization of a protein is the 
formation of well-ordered crystals. This requires specific intermolecular interactions of 
one molecule to another one. In contrast to soluble proteins which can use their 
entire surface for crystal contacts, membrane proteins have often only a limited 
surface to form such contacts, namely the small hydrophilic surface loops. Normally, 
the detergent molecules which form a micelle around the hydrophobic region, which 
is the major part of the surface for many membrane proteins, do not form crystal 
contacts. Furthermore, membrane proteins often adopt several conformations in 
order to fulfill their transport function.   
 
One way to enhance the chance of crystallizing a membrane protein is to use 
either a natural ligand, a synthetic binding molecule or a bioengineered protein 
ligand. The complex formation of a target molecule with a binding protein can have 
several beneficial effects: (i) a thermodynamic stabilization of the target, (ii) a 
stabilization of a particular conformation, and (iii) an enlargement of the hydrophilic 
surface. Furthermore, the protein complex can form different crystal contacts in 
comparison to the single protein, due to the altered surface. However, most of natural 
interaction partners are not known, not easy to obtain or not suitable for 
crystallization in terms of affinity, homogeneity, flexibility etc. or in many cases there 
is no natural binding partner at all. The desire to use synthetic or engineered ligands 
therefore is easily explained. Antibodies or fragments thereof are the best-known 
binding molecules. They have been used to determine crystal structures of soluble 
proteins and membrane proteins complexes [2, 3].  
 
However antibodies and antibody fragments are not ideal for use in structural 
biology because of several reasons. These limitations have prompted the search for 
alternative frameworks with the same binding capabilities, but with superior 
properties to antibodies. One of these alternative frameworks is the designed ankyrin 
repeat proteins (DARPins). 
 
A general introduction into designed ankyrin repeat proteins and their 
successful application for the structure determination of diverse proteins is reviewed 
in the following publication. 
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The structure of proteins that are difficult to crystallize can often be solved by forming a 
noncovalent complex with a helper protein – a crystallization “chaperone”. Although 
several such applications have been described to date, their handling usually is still very 
laborious. A valuable addition to the present repertoire of binding proteins is the 
recently developed designed ankyrin repeat protein (DARPin) technology. DARPins are 
built based on the natural ankyrin repeat protein fold with randomized surface residue 
positions allowing specific binding to virtually any target protein. The broad potential of 
these binding proteins for X-ray crystallography is illustrated by five cocrystal 
structures that have been determined recently comprising target proteins from distinct 
families, namely a sugar binding protein, two kinases, a caspase, and a membrane 
protein. This article reviews the opportunities of this technology for structural biology 
and the structural aspects of the DARPin-protein complexes.  
 
Despite the continuous technical advances in protein crystallography due to the worldwide 
effort in structural genomics programs that promote the application of automated procedures 
in cloning, expression, purification, crystallization, data collection using synchrotron radiation 
and computational crystallography, the determination of some protein structures still remains 
a difficult task. Today, the main limitation is the growth of well-diffracting crystals - a pure 
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trial-and-error process – because the formation of protein crystals depends on several 
unpredictable variables. In particular, advances in microscaling methodology involving 
pipetting robots and automated imaging of individual experiments have allowed high 
throughput approaches boosting the field. However, even with these advances, many proteins 
resist forming suitable crystals on their own because of inherent structural flexibility and 
instability. Consequently, conformation stabilizing methods that help to crystallize proteins 
seem attractive.  
Approaches in this direction are removal or mutation of surface residues known to be flexible 
(Lawson et al., 1991), the trimming of the protein’s often flexible N- and C-terminal ends, or 
the analysis of stable domains of larger multi-domain proteins (Derewenda, 2004). Another 
successful approach to promote the crystallization of a particular protein has been the addition 
of a conformation-stabilizing ligand. Current crystallization tools include the building of 
complexes with diverse known natural or synthetic ligands, such as substrates, inhibitors, 
nucleic acid, cofactors, or protein ligands. The benefits of such noncovalent complexes can be 
manifold. A specific conformation of the target protein may be stabilized in such a complex. 
This increases the chances to obtain crystals of proteins that otherwise adopt several 
conformations and therefore resist forming crystals. In addition, novel surfaces can potentially 
provide better crystal contacts. Especially for membrane proteins, protein ligands also 
increase the hydrophilic surface area of an otherwise small non-transmembrane region. This 
strategy for the crystallization of membrane proteins has repeatedly led to successful structure 
determinations, as seen for many antibody fragment-membrane protein complexes (Dutzler et 
al., 2003; Hunte et al., 2000; Iwata et al., 1995; Zhou et al., 2001). Cocrystallization of a 
target protein in complex with a proteinaceous ligand of known structure potentially provides 
another advantage, namely the structure solution by molecular replacement allowing to avoid 
the often time-consuming determination of phases via heavy atoms as in single/multiple 
anomalous dispersion or multiple isomorphous replacement (MIR) techniques. 
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DNA and RNA binding proteins are often cocrystallized with their natural binding partner, 
fragments of DNA or RNA stabilizing the conformation of the protein (Anderson et al., 
1984). In many cases however, the protein of interest lacks a natural binding partner, the 
natural binding partner might not be known or it might not be available for other reasons. 
Therefore, proteinaceous ligands, either natural or synthetic, have received a great deal of 
attention in the field of structural biology. Antibody and fragments thereof are the most 
successful molecules to be used as high-affinity and specific binding proteins in biomedical 
research and have not only been used as a binding protein but also assist in crystallization 
(Amit et al., 1986). In 1995, Ostermeier et al. selected monoclonal antibodies for the first time 
against a membrane protein, namely cytochrome c oxidase of Paracoccus denitrificans, 
finally allowing the successful structure determination of the oxidase in complex with a Fv 
fragment (Iwata et al., 1995; Ostermeier et al., 1995). In addition to the well-known Fab and 
Fv fragments, single-chain antibody domains such as camelid VHH fragments or scFvs led to 
successful structure determinations (Desmyter et al., 1996; Kortt et al., 1994). Recently, 
several studies using nonantibody scaffolds such as affibodies (Hogbom et al., 2003; 
Wahlberg et al., 2003), monobodies (Koide et al., 2007), and repeat proteins (Binz et al., 
2004) have shown that these molecules are potential alternatives to antibody fragments in 
structural biology. These binding molecules were developed as tools for basic research, but 
their potential use in commercial applications (as specific reagents in biomedical research and 
as potential therapeutic molecules) was immediately apparent and quickly recognized (Gill 
and Damle, 2006). Many novel binding proteins have improved on the limitations of 
antibodies, in particular their rather low production yield and intrinsic stability. 
Simultaneously, they retain the beneficial properties of antibodies, namely specific and tight 
binding. Structural biologists likewise have a great interest in using these molecules as 
chaperones in crystallization. 
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In this review, we focus on one scaffold, the DARPins. The potential of DARPins as 
promising compounds in drug discovery and drug development has been reviewed recently 
(Stumpp and Amstutz, 2007). We examine the five recently determined X-ray structures of 
DARPin complexes and address several questions concerning DARPin-target interactions. 
The diversity of the successfully chosen antigens is paralleled by the diversity of the 
interaction partners of natural ankyrin repeat proteins, which indicates that the technology can 
be generally applied to a very broad range of target molecules.  
 
Drawbacks of antibodies 
The main advantage of antibodies is their ability to recognize a wide range of target molecules 
with high affinity and specificity. Besides proteins, antibodies can bind compounds such as 
peptides, sugars and small molecules. However, natural antibodies are complex multidomain 
molecules not well suited for cocrystallization due to their flexible linker regions between 
domains and their bivalent character. Therefore, only antibody fragments have been applied 
for cocrystallization purposes. Fab or Fv fragments contain the complete antigen recognition 
sites and are therefore sufficient to retain the specific antibody-antigen interaction. 
Nevertheless, these fragments often derive from monoclonal antibodies, and their classical 
production by hybridoma technology is time-consuming, expensive, and based on the use of 
living organisms. The selection using recombinant and synthetic libraries have facilitated their 
generation (Rothe et al., 2008) and let to successful structure determinations (Fellouse et al., 
2007; Fellouse et al., 2005; Fellouse et al., 2004; Ye et al., 2008) but the complicated 
multidomain molecular architecture with disulfide bonds still complicates their handling, 
limits their use in reducing environments and requires special production precautions in 
bacterial expression systems such as expression in the periplasm to guarantee the correct 
disulfide bond formation. This often affects the production yield since the volume of the 
periplasm is limited. Despite these difficulties there are numerous structures in complex with 
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soluble target proteins (Bentley, 1996) as well as more demanding membrane proteins (Hunte 
and Michel, 2002) but the problems associated with all antibody-derived crystallization 
chaperones inspire continuously to search for alternative binding proteins with similar binding 
capabilities but superior properties regarding structure, stability and throughput. 
 
What are DARPins?  
DARPins are derived from the ankyrin repeat motif present in numerous naturally occurring 
proteins. In nature, ankyrin repeat containing proteins are involved in a wide variety of 
biological activities and are present in all three superkingdoms (Bork, 1993). Best 
documented is their involvement in specific protein-protein interactions. The diversity of their 
roles in a cellular context is further reflected in their localization, which can be the nucleus, 
cytoplasm and the extracellular space, where these proteins interact with a large diversity of 
partners. The number of repeats presented in a single ankyrin repeat protein and thus involved 
in binding is highly variable so that ankyrin domains can bind to host target molecules that 
vary considerably in size and shape.  
The 33-residue sequence motif of an ankyrin repeat forms a well-defined architecture, 
consisting of a -turn, followed by a pair of antiparallel -helices and a loop that builds the 
connection to the next repeat (Figure 1A). The characteristic secondary structure components 
fold into an L-shaped conformation where the helices form the stem and the loop projects 
outward at an angle of about 90°. Not uncommon are insertions between or within repeats, 
mainly in the -turn/loop region (Sedgwick and Smerdon, 1999). These insertions can be 
either a short helical segment or more complex motifs. The fully assembled ankyrin domain is 
elongated and slightly curved, manifested particularly in high repeat number ankyrin repeat 
proteins (Figure 1B). In naturally occurring complexes involving ankyrin repeat proteins, the 
concave surface, formed by the -turn and the first -helix, is commonly involved in binding 
the target molecules as shown by the X-ray structures determined to date: p16INK4a-CDK6 
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(Russo et al., 1998), p19INK4d-CDK6 (Brotherton et al., 1998; Russo et al., 1998), GABP-
GABP-DNA (Batchelor et al., 1998), IB-NFB (Huxford et al., 1998; Jacobs and 
Harrison, 1998; Malek et al., 2003), p18INK4c-CDK6 (Jeffrey et al., 2000),  CSL-Notch-
Mastermind (Wilson and Kovall, 2006), Nas6-Rpt3 (Nakamura et al., 2007b), Gankyrin-S6 
(Nakamura et al., 2007a). 
Recently, Plückthun and coworkers have chosen the traits of ankyrin repeat proteins for 
consensus-based protein library design (Binz et al., 2003). Heeding the lessons of nature, they 
created DNA libraries that encode DARPins consisting of different numbers of repeat 
modules and special capping repeats attached to the N and C termini of the protein (Figure 
1B). Therefore, the molecules are termed NxC, where x indicates the number of ankyrin 
repeat modules. The consensus-designed idealized repeat module consists of conserved 
residues essential for the formation and stabilization of the repeat module itself and the 
interrepeat stacking interactions. These positions are invariant and build the framework of the 
individual repeats. In addition, positions not contributing to the structural integrity of the basic 
fold were defined to be adaptive surface residues (Figure 1A). These residues are positioned 
at the typical interface region of the natural ankyrin repeat, namely the tip of the -turn and 
along the exposed surface of the first -helix (Figure 1C). At these positions, the introduced 
diversification allows any amino acid except proline and glycine (structurally unfavorable) 
and cysteine (could form unwanted disulfide bonds). This design resulted in a virtually 
unlimited repertoire of molecular surfaces.  
 
Selection process 
Rapid and easy production is a prerequisite for alternative scaffolds suitable for co-
crystallization. Repeat protein libraries (Binz et al., 2004; Binz et al., 2003) can be selected 
using powerful library selection technologies such as ribosome display (RD) (Hanes and 
Plückthun, 1997) or phage display (Smith, 1985), finally yielding specific binders to the target 
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protein. RD is a complete in vitro technology based on in vitro translation in which 
noncovalent ternary complexes consisting of mRNA, ribosome, and nascent protein chain are 
formed. These ternary complexes can then be tested for binding to a particular target protein. 
This system thereby guarantees the coupling of the genotype (mRNA) to the phenotype 
(protein) and allows immediate access to the genetic information of the binders. To achieve 
this, the coding sequence of the protein is genetically fused to a C-terminal spacer, allowing 
the correct folding of the nascent protein polypeptide chain, and the construct lacks a Stop 
codon, thus preventing release of the mRNA and the polypeptide from the ribosome. Low 
temperature and high concentrations of magnesium further stabilize the ternary complexes. 
The disassembly of the complexes results from depletion of magnesium, and the DNA is 
recovered via reverse transcription. RD is particularly well suited for large libraries, because 
no transformation steps limit the applicable library size. Furthermore, as a cell-free system, it 
enables the selection of cytotoxic proteins or of proteins with limited in vivo stability. 
All the DARPin binders presented here were isolated from an N3C library and were selected 
by RD. DARPin binders could also be successfully selected from an N2C library, but these 
did not yield crystals. Ankyrin repeat proteins consisting of four to five repeats in total are 
very abundant in nature (Bork, 1993) and also many of the solved natural ankyrin repeat 
structures in complex with their target display such repeat numbers. The target proteins 
chosen here were all recombinantly expressed, purified, and either in vivo biotinylated at a 
specific lysine in the AviTag sequence (MBP, APH, and Caspase-2), in vitro biotinylated at 
diverse lysines on the surface (AcrB) or GST-tagged (Plk-1) for immobilization. Within a few 
RD cycles (usually 3 to 4), it was possible to enrich the resulting residual library with proteins 
that specifically and with high affinity bind to the target.  
A subset of the DARPins obtained by RD was then tested individually for binding using 
approaches suitable for the particular target protein or the intended use of the binder. For 
MBP (Binz et al., 2004) and Plk-1 (Bandeiras et al., 2008), a standard ELISA was applied to 
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identify a high-affinity binder. In the case of caspase-2, an in vitro enzymatic activity test 
combined with a standard ELISA yielded an inhibitor (Schweizer et al., 2007). For APH 
(Amstutz et al., 2005; Kohl et al., 2005) and AcrB (Sennhauser et al., 2007), an in vivo assay 
was applied in which the inhibition of the target protein through the DARPins resulted in 
hypersusceptibility of the bacteria. Normally, the DNA of around 20 DARPins obtained from 
these assays was sequenced per target. The pools often seemed already quite enriched, 
revealing groups with similar sequences, although identical sequences were rarely observed. 
Depending on the sequence variability, five to ten complexes were then purified (yields 
between 50 and 200 mg/l), characterized, and subjected to crystallization. 
 
Structures of DARPins in complex with different antigens 
Maltose-binding protein: proof of principle  
As a model protein for the approach of selecting a specific DARPin protein by RD, the 
maltose-binding protein from Escherichia coli was chosen and represents the first successful 
example for the selection and crystallization of a particular target protein in complex with a 
DARPin. The structure of the complex was determined at 2.3 Å resolution and the phases for 
this structure could be determined using a known structure of an unselected DARPin 
previously solved (Kohl et al., 2003). This was possible because the size of the DARPin (~18 
kDa) relative to the size of maltose-binding protein (~43 kDa) was appropriate and there was 
only one complex in the asymmetric unit. Off7 binds the open form of MBP not involving the 
sugar-binding cleft but binding three helices at one side of the elongated MBP (Figure 2A). 
Four lysines forming a positive surface patch which account for 60 % of the buried surface 
area of MBP upon complexation interact closely with off7 (Figure 3A). 
This first structure showed that the interface between the selected DARPin off7 and MBP 
indeed involves primarily residues from all three randomized repeat modules with the 
randomized repeat module 2 contributing most to the binding (Figure 4A). The two capping 
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repeats are not involved in the interaction. The binding interface is comparable to the lower 
limit of natural protein-protein interactions (Jones and Thornton, 1996) (Table 1) and is 
formed by the concave surface of off7 and a convex surface of MBP. It involves mainly 
amino acids at the randomized positions. Off7 contains three framework mutations, of which 
one (H125Y) is involved in MBP binding. The interface on the DARPin is further 
characterized by seven aromatic residues, four of these tyrosines, which account for 72% of 
the buried surface area of off7 upon complexation. 
 
Aminoglycoside phosphotransferase (3’)-IIIa: the first inhibiting DARPin 
The bacterial kinase aminoglycoside phosphotransferase (3’)-IIIa (APH) mediates antibiotic 
resistance to many pathogenic bacteria and is structurally homologous to eukaryotic protein 
kinases. A highly affine and potent intracellular kinase inhibitory DARPin, named 3a, was 
selected (Amstutz et al., 2005) and the structure of APH/3a with bound ADP was determined 
at a resolution of 2.15 Å with two heterodimeric complexes in the asymmetric unit. The 
DARPin binds to two helical segments in the C-terminal lobe of APH (Figure 2B and 3B). 
On the DARPin surface, the interaction residues are located mainly on the N-terminal capping 
repeat, on repeat modules 1 and 2, and, to a lesser extend, on module 3 (Figure 4A). As for 
MBP/off7 there are no interactions involving the C-terminal capping repeat, and as a 
consequence there was only weak density visible for this part of the molecule, indicating 
flexibility.  
Whereas the structure of the DARPin is not affected by the binding (Figure 4B), 3a binds to 
the two helices A and B in the -helical C-terminal lobe of APH, thereby stabilizing helix D 
in a conformation unable to bind substrate (Figure 5A). In addition, the aminoglycoside 
positioning loop connecting helices A and B is disordered. The structure of the C-terminal 
lobe of the complex differs significantly from the structure of APH alone. This affects in 
particular the C-terminal amino acid Phe264 of helix D which is critically involved in 
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substrate binding as revealed by the kanamycin A bound APH structure (Hon et al., 1997). In 
the DARPin complex, this interaction is distorted, and thus the enzyme is unable to bind the 
antibiotic.  
 
Polo-like kinase-1: an arduously crystallizable target 
The Ser/Thr protein kinase polo-like kinase-1 (Plk-1) is a key regulator of mitosis and is a 
well-validated drug target in cancer therapy. Crystallization attempts for various constructs of 
the wild-type kinase domain of Plk-1 using a multi-parallel cloning and expression approach 
have failed in the past. Therefore, binders from a DARPin library selective for Plk-1 have 
been generated and have been used in cocrystallization trials. In this way, the first structure of 
wild-type apo Plk-1 could be determined in complex with the DARPin 3H10 at 2.3 Å 
resolution with two complexes in the asymmetric unit. The DARPin binds to the C-terminal 
lobe of the kinase directly below the ATP binding site (Figure 2C). The binding epitope 
recognized by DARPin 3H10 is especially rich in Arg, Lys and Glu residues (66% of the 
buried surface area) enabling crystallization by masking a surface patch of Plk-1 that is 
unfavourable for forming crystal contacts similar to the surface residue mutation method 
(Figure 3C). Such residues have high conformational freedom and are considered 
counterproductive for crystal contact formation due to a loss of entropy (Derewenda and 
Vekilov, 2006). As revealed by isothermal calorimetry measurements, the overall interaction 
is endothermic and apparently driven by entropy alone. 
The three repeat modules are solely responsible for the interaction, and again there are mainly 
residues at the randomized positions involved (Figure 4A). The N-terminal capping repeat is 
not involved in binding. Interestingly, the C-terminal capping repeat is fully disordered in the 
structure either due to the binding of the kinase or due to clashings with the 
noncrystallographic symmetry-related DARPin during crystal formation.  
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Caspase-2: the first specific Caspase-2 inhibitor 
Caspases are key molecules in the signaling of apoptosis and inflammation. The DARPin F8 
was found to inhibit caspase-2 with a subnanomolar inhibition constant. In addition, testing 
inhibition against other caspases showed that F8 was highly specific exclusively for caspase-
2. The structure of the caspase-2/F8 complex at 3.24 Å resolution revealed the molecular 
basis for the specificity as well as the allosteric mechanism of inhibition which was also 
verified by kinetic analysis. The asymmetric unit contained three caspase-2 dimers with two 
bound DARPins each (Figure 2D). The main contact surface of caspase-2 is formed by the 
381 loop, involving diverse residues (Figure 3D). Minor interactions involve the N-terminus 
of the other -subunit of the caspase. Regarding F8, all three repeat modules and one 
framework residue in the N-terminal capping repeat are forming the interface on F8 (Figure 
4A).  
The 381 loop forms one side of the active site cleft (Figure 5B). The conformation of this 
loop is slightly shifted when compared to the caspase-2/peptide inhibitor structure (Schweizer 
et al., 2003), resulting in an opening of the active site cleft. Additional rearrangements in the 
surrounding of the active site cleft and the side chain of Tyr79 of F8 occupying partly the 
substrate subpocket S5 of caspase-2 are the main reasons for the inhibitory property of F8. 
The caspase-2/F8 complex shows that the allosteric inhibition of caspase-2 is extremely 
specific, which has significant advantages over orthosteric ligands which often lack 
specificity.  
 
AcrB: the first integral membrane protein in complex with a DARPin 
The multidrug exporter AcrB, the inner membrane component of the AcrAB-TolC drug efflux 
system in Escherichia coli is the major system contributing to efflux-caused drug resistance in 
this organism. This protein actively detoxifies the intracellular space by exporting drugs to the 
cell exterior while importing protons. To explain the molecular mechanism of this process, the 
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availability of high-resolution structural information is a prerequisite. For this, and to show 
the applicability of the DARPin combinatorial libraries and of the ribosome display selection 
method to membrane proteins, AcrB was chosen as model system. Although AcrB can be 
crystallized on its own due to its large periplasmic domain protruding from the lipid bilayer, 
the crystals of the AcrB/110819 complex diffracted to 2.54 Å resolution, substantially better 
than all the previously published crystals of AcrB alone (Murakami et al., 2002). In the 
structure, the DARPin binds to the periplasmic part of AcrB and due to the distinctly different 
conformations of the subunits only two DARPins bind to the trimeric protein (Figure 2E). 
The epitope on AcrB is mainly formed by a -sheet connecting the pore domain with the 
TolC docking domain, which are subdomains of the periplasmic portion of the protein 
(Figure 3E). An additional interaction is formed involving a helical segment and a -strand of 
the adjacent preceding subunit of AcrB via hydrophobic interactions and two hydrogen bonds. 
All five repeats (including both capping repeats) of the DARPin are involved in the 
interaction (Figure 4A). Comprising around 1100 Å2 buried surface area on both the DARPin 
and AcrB, and 68 residues in total, this complex showed the largest buried surface area for a 
DARPin complex so far (Table 1).  
Interestingly, the structure revealed a new conformation of the molecule where the three 
subunits of AcrB were locked in different conformations, revealing distinct channels in each 
subunit. Furthermore, the structure indicated how in the protein the coupling between the 
channel access, exit, and the putative proton translocation site is achieved. It suggests a 
transport pathway through the identified channels in the individual subunits by a rotary 
mechanism. At the same time, this new conformation was also observed without a bound 
DARPin by two individual groups (Murakami et al., 2006; Seeger et al., 2006). In further 
studies, DARPin 110819 also allowed the crystallization of otherwise uncrystallizable 
mutants (K.M. Pos, unpublished data). 
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General properties of DARPin-target interfaces 
The structural properties forming the surface of the target proteins recognized by DARPins 
vary from complex to complex (Figure 2). A common trait between the different interfaces, 
however, is the overall curvature of the target protein interface area enclosed by DARPins. 
This curvature is complementary to the curvature of the randomized surface area of the 
DARPin. Furthermore, all three internal randomized repeat modules are involved in the 
interaction in all five complexes (Figure 4A). As set out in the design, the predominant 
interaction is mediated by residues in the randomized positions (Figure 4C); this is then also 
the reason for the high specificity of the selected molecules. Interestingly, the last residue of 
the individual repeat module, namely randomized position 33, is not involved in any interface. 
In contrast, position 3 is heavily buried in most of the repeat modules. In all complexes, 
framework residues also participate in the interaction with the target protein. In the case of the 
MBP and AcrB binders, there is a mutated framework position H125Y and D155N,  
respectively, contributing to the interaction. Such framework mutations can be explained as a 
result of the numerous PCR cycles the DARPin-encoding DNA passes during the selection 
process.  
The involvement of the capping repeats in the interaction differs greatly between the different 
complexes. Whereas the N-terminal capping repeat is well ordered in all structures and 
involved in binding in the APH, caspase-2 and AcrB complexes, the C-terminal capping 
repeat is fully disordered in the Plk-1 complex and partially disordered in the APH and 
caspase-2 complex. It is solely involved in the AcrB/110819 complex, where 7 residues of the 
C-terminal capping repeat are participating in the interface. In having the first interacting 
residue at position 13 and the last at position 157, the full width of the 169 amino acid residue 
DARPin is used in this complex. This provides the most extensive interaction described to 
date.  
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The structures discussed here show that DARPins are not restricted to recognize any specific 
amino acid sequence or structure on the target. In all cases, the DARPins recognize native, 
nonlinear epitopes (Figure 3). There is no particular chemical character found neither for the 
epitopes (target interface) nor for the paratopes (DARPin interface). There are numerous 
aromatic residues on the paratopes, but they seem to be less preferred than in antibody 
paratopes (Padlan, 1990). An exception is the MBP-off7 complex where the aromatic residues 
account for 72% of the buried surface area of the DARPin. The proportion of aromatic 
residues in the epitopes is low, a fact that has been observed in antibody-antigen interactions 
as well (Davies and Cohen, 1996). Furthermore, charged residues seem to be important for the 
interaction, accounting for nearly half of the contact residues of the epitopes. Whereas all 
DARPins described here are composed of five repeat modules, the total interface sizes on the 
target molecules differ widely. The MBP/off7 complex presents by far the smallest interface, 
comprising 40 residues and a combined buried surface area of only 1264 Å2 (Table 1). In 
contrast, the largest interface observed in the AcrB/110819 complex comprises 63 and 68 
residues and buries 1986 and 2328 Å2 of the AcrB surface in the two interfaces formed; all 
other complex interfaces are in between these values. However, the interfaces show great 
similarities to naturally occurring ankyrin repeat protein, heterodimeric protein-protein, and 
antibody-antigen complexes (Table 1).   
 
Structural rearrangements in the target proteins and the DARPins 
An often raised argument in the field of chaperone-assisted crystallization is that binders 
might induce a conformational change in the target molecules. Because the crystal structures 
of all target proteins chosen are available also without a binding partner, it is possible to 
investigate conformational changes of the targets on DARPin binding. The structures of MBP 
in the open conformation without a ligand (PDB ID code: 1LLS; (Rubin et al., 2002)) and 
complexed MBP are very similar, with an overall C rmsd below 1 Å. Also, in the case of 
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AcrB, the structures obtained in 2006 (Murakami et al., 2006; Seeger et al., 2006) are 
remarkably similar, considering the size of the protein (rmsd for 3110 C atoms ~ 1 Å). In 
addition, the observed asymmetry in the crystal structure could also be detected in solution 
(Sennhauser et al., 2007). The overall structure of Plk-1 is also very similar to two structures 
of a mutant solved at the same time, each harboring a different ligand (Kothe et al., 2007), 
again indicating that there is no binding protein induced conformational change.  
The interaction of the DARPin inhibitors with APH and caspase-2 revealed conformations in 
which the target proteins were inactive. This information is useful for finding novel ways to 
inhibit the function of an enzyme. The structural rearrangements there are quite considerable. 
In APH, helices A, B, and D are significantly shifted with respect to kanamycin A bound 
APH (Hon et al., 1997), and the aminoglycoside positioning loop connecting helices A and B 
is disordered (Figure 5A). In caspase-2, the loops surrounding the active site cleft are altered 
when compared to the caspase-2/peptide inhibitor structure (Schweizer et al., 2003), resulting 
in an opening of the active site cleft (Figure 5B). Nevertheless, we do not believe that these 
structural rearrangements are caused by the DARPin, resulting in an induced fit. Recalling the 
DARPin selection strategy, it is more likely that the DARPins only bind to epitopes as 
presented by the target proteins in a “lock-and-key” like fashion. In this way, the selected 
DARPins can bind to proteins not only in their predominant conformation but also can trap 
the proteins in conformations which are probably present in solution but less populated thus 
inhibiting an enzyme in an allosteric way. 
In all structures, the differences in the DARPin scaffold are minimal upon binding and 
showed no essential rearrangements of the global fold compared to an unselected DARPin 
alone (Kohl et al., 2003) (Figure 4B).  In agreement with the participation of the individual 
repeats in the interaction, the strongest flexibility can be observed in the C-terminal capping 
repeat. In the DARPin binding Plk-1, the C-terminal capping repeat cannot even be localized 
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in the crystal structure. The -turn regions of the individual repeat modules also show some 
minor adaptations when bound to a target protein.  
 
DARPin mediated crystal contacts 
The potential of DARPins to provide crystal contacts is best described for the MBP/off7 and 
the AcrB/110819 complex. As shown in Figure 6A, in the MBP/off7 complex the lattice 
interactions involve only DARPin-DARPin and MBP-MBP contacts, which occur within 
layers, and the direct binding interface between the two interaction partners is the sole contact 
form between the layers.   
In the crystal formed by the AcrB/110819 complex, crystal contacts are mediated by the 
DARPin in such a way that, in addition to the interaction with the periplasmic domain of its 
target, the convex side of the DARPin simultaneously forms crystal contacts to the 
cytoplasmic polar surface of a symmetry-related molecule of AcrB (Figure 6B). Because the 
crystal has the space group P212121, this contact critically contributes to the stability of the 
lattice (the mentioned contact occurs in all three dimensions) and thus to the higher diffraction 
limits of the complex crystal over the crystal formed by AcrB alone. 
There are some proteins that could be crystallized only when complexed to a cognate Fab 
fragment (Laver et al., 1990). A similar case is Plk-1 that alone in its apo-form-a structure 
most useful for drug design-did not crystallize. In complex with the DARPin 3H10, however, 
Plk-1 did crystallize. Surprisingly, the DARPin makes direct crystal contacts to the other 
DARPin in the asymmetric unit via the third repeat module as the C-terminal capping repeat 
is fully disordered (Figure 6C). 
It is worth mentioning that cocrystallization with a DARPin clearly was advantageous in the 
cases of AcrB and Plk-1, whereas the opposite was true for caspase-2. Here, the diffraction 
quality of the DARPin complex was clearly worse (3.24 Å) than caspase-2 in complex with a 
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peptide inhibitor (1.65 Å) (Schweizer et al., 2003). DARPins containing different numbers of 
internal repeats might be selected to obtain better diffracting crystals.  
 
Conclusions 
We have reviewed the recent results using DARPins as crystallization tools to crystallize 
difficult target proteins to understand the natural and alternative conformations of these 
proteins. DARPins are a class of designed binding molecules that represent a very promising 
alternative to antibodies. They retain the affinity and specificity of antibodies but are far more 
stable, and their simple architecture allows high-yield bacterial production. Their use in 
biomedical and biotechnological research is considerably more advantageous over antibodies. 
High-affinity DARPins to a given target can rapidly be selected from very large libraries 
within a few weeks. The use of in vitro selection systems such as phage or ribosome display 
represents an advantage over the traditional production of monoclonal antibodies in test 
animals, as the binders are selected to a native protein under defined buffer conditions. 
Therefore, the in vitro display techniques guarantee that surface epitopes of the presented 
target protein are selected. The use in structural biology is obvious from the structures 
described here, and not only enables crystallization of soluble and membrane proteins but also 
reveals conformations of the target proteins that otherwise are not detected when inhibitors 
are selected. In the cases of DARPin inhibitors of caspase-2 and APH, the crystals of the 
complex did not diffract better; rather, the diffraction was rather worse than of crystals of the 
target proteins with small molecule compounds bound to the active site. However, in both 
cases a conformation of the target protein was revealed in which the protein is inactive. This 
information is useful for finding new ways to modulate target protein function.   
To expand the applicability of the technology in protein crystallography, heavy atom sites can 
be engineered into the capping repeats. Crystals of target proteins with a heavy atom-loaded 
DARPin is a great help in phasing using the single anomalous dispersion method. This has 
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already been successfully applied using a DARPin-MBP complex crystal (A. Plückthun and 
M.G. Grütter, unpublished data). 
In conclusion, DARPins have the potential to (1) provide crystals of a target protein that is 
difficult to crystallize, (2) provide better diffracting crystals of the complex when the target 
protein alone only poorly diffracts, (3) provide initial phases for molecular replacement in 
cases where the DARPin and the target protein are not too different in size, (4) provide phases 
by single anomalous dispersion for complexes formed with heavy atom loaded DARPins, and 
(5) reveal new insight into the function of a target protein by stabilizing a conformation that in 
solution is less populated. 
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Table 1. Structural features of the interfaces of DARPin-protein complexes 
 
 
Complex KD (nM)b Resolution 
 (Å) 
Nres Buried surface area (Å2) Percentage of total 
surface area (%) 
NHB NSB
   Target DARPin Total Target DARPin Total Target DARPin 
1svx             
MBP-off7 (B-A)a 4.4 2.3 19 21 40 649 615 1264 4.2 8.1 8 2 
2bkk             
APH-3a (A-B) 1.7 2.15 21 27 48 925 850 1775 6.7 10.8 15 8 
2v5q             
Plk1-3H10 (A-D) 75 2.3 21 25 46 857 885 1742 6.0 14.3 14 9 
2p2c             
C2-F8 (BDA-P) 4.1 3.24 25 26 51 937 885 1822 12.1 10.2 8 9 
C2-F8 (DBC-Q)   23 25 48 830 809 1639 10.5 9.7 6 9 
2j8s             
AcrB-110819 (BA-D) 28 2.54 35 33 68 1142 1186 2328 2.5 15.3 12 3 
AcrB-110819 (AC-E)   32 31 63 969 1017 1986 2.2 13.4 11 2 
Antibody-antigenc   777 ± 135   8.2 ± 0.7  
Heterodimeric protein-
protein complexesc 
  983 ± 582   11.1 ± 2.7  
Analyzed with the Protein Interfaces, Surfaces and Assemblies service PISA. The numbers may be at variance 
with those found by the original authors owing to different programs used. Only the interface features of one 
complex are shown when there were several complexes in the asymmetric unit. 
a Characters in parentheses show the chains participating in the interface as designated in the PDB file (target -
DARPin). 
b Affinities were determined by BIAcore technology. For Plk-1-3H10 a KD measured by competition ELISA was 
described. 
c According to (Jones and Thornton, 1996). The values for NHB were calculated from the tabulated hydrogen 
bonds/100 Å2 ASA.  
 
Nres – number of residues from the specified molecule that take part in the interface; NHB – number of potential 
hydrogen bonds across the interface; NSB – number of potential salt bridges across the interface.  
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Figure 1 
 
 
 
 
 
 
 
Figure 1. Structure and potential interaction surface of a DARPin 
 
(A) Ribbon representation of a designed ankyrin repeat module. The side chains of the six randomized 
positions and the randomized framework residue (position 26) are shown as yellow sticks, and their 
positions within the 33-amino acid conserved framework are labeled. Side chains of the conserved 
residues are not shown for clarity. 
(B) An N3C DARPin library member. The three repeat modules are colored purple; the capping 
repeats are colored blue. The randomized positions, located mainly in the -turns and the first -
helices of the individual repeat modules, are shown as yellow sticks. 
(C) Randomized potential interaction surface of an N3C DARPin that normally provides the 
interaction site (in yellow). The orientation is the same as in (B).  
All figures were prepared with PyMol (DeLano, 2002). 
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Figure 2 
 
 
 
 
Figure 2. Open book illustrations of 
the interaction surfaces of DARPins 
and their respective target molecules 
 
(A)-(D) Center: ribbon diagrams of the 
X-ray structures of the individual 
complexes. Target proteins and 
DARPins are colored blue and purple, 
respectively. Interfaces are highlighted 
in yellow. Left: The targets have been 
rotated clockwise. Right: The DARPins 
have been rotated counterclockwise. 
Residues that approach within 4 Å of the 
interaction partner are colored by 
element (C, N, and O atoms are colored 
yellow, blue, and red, respectively).  
(A) DARPin off7 in complex with MBP 
(PDB entry code 1svx). 
(B) DARPin 3a in complex with APH 
(PDB entry code 2bkk). 
(C) DARPin 3H10 in complex with Plk-
1 (PDB entry code 2v5q). 
(D) DARPin F8 in complex with 
caspase-2 (PDB entry code 2p2c). 
Caspase-2 is colored dark blue for the 
-subunits and light blue for the -
subunits. 
(E) DARPin 110819 in complex with 
AcrB (PDB entry code 2j8s). The AcrB 
subunits A, B, and C are colored dark
blue, light blue, and gray. Left: AcrB 
has been translated. Right: the DARPin 
has been rotated counterclockwise. 
Residues that approach within 4 Å of the 
DARPin are colored by element.  
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Figure 3 
 
 
 
Figure 3. Comparison of the 
epitopes on the different target 
molecules 
 
Stereo view of the targets of the 
complexes. The molecules are shown 
in ribbon representation in the same 
orientation as in the left panel of 
Figure 2. Interfacing residues (4 Å
distance cutoff) are shown as sticks 
and are colored by element. 
(A) MBP  
(B) APH  
(C) Plk-1  
(D) Caspase-2 
(E) Close-up view of AcrB 
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Figure 4 
 
Figure 4. Structural differences between the binding DARPins 
 
(A) Contribution of each repeat to the buried surface area of the paratope. 
(B) Structures of the DARPins bound to the diverse target molecules. The C atoms of the DARPins 
were least-squares superimposed using the program coot and are shown in worm representation. The 
termini are labeled. The DARPins are colored as follows: red, unselected DARPin; orange, off7; 
yellow, 3a; green, 3H10; cyan and light blue, F8 molecules P and Q; dark blue and gray, 110819 
molecules D and E. 
(C) Amino acid sequence alignment of the DARPins. Positions marked with X and Z in the consensus 
represent the randomized positions where in the case of X any amino acid (except Cys, Gly, and Pro) 
or in the case of Z Asn, His, and Tyr is allowed. Residues marked in yellow and green indicate those 
involved in binding of the target in the crystal structure (distance < 4 Å; in green: accounts for more 
than 5% of the total buried surface area upon complex formation).  
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Figure 5 
 
 
 
 
 
 
 
 
Figure 5. Conformations of the target molecules 
 
(A) Close-up view of the superposition of the DARPin binding region of APH in complex with 
DARPin inhibitor 3a (blue and purple) and wtAPH (gray). The APH/3a complex displays a distorted 
drug binding site. The -helices A and B in the C-terminal lobe of APH interacting with the DARPin 
are shifted, and the aminoglycoside positioning loop between these two helices is disordered. This 
rearrangement leads further to a 5- to 7-Å shift of helix D with respect to wtAPH which includes the 
C-terminal residue Phe264. Kanamycin A bound to wtAPH is shown in yellow, and hydrogen bonds 
to the mainchain carboxyl group of Phe264 are indicated as dashed lines. 
(B) Close-up view of the active-site cleft region of caspase-2. Superimposed caspase-2 bound to Ac-
LDESD-CHO (colored in gray and yellow), and to the DARPin F8 (colored in blue and red) is shown. 
In the DARPin-bound form, the loop 381 and the C-terminal part of the  subunit (C), which 
includes the active site cysteine, are shifted with respect to the peptide bound form.  
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Figure 6 
 
 
 
 
 
 
 
Figure 6. Diverse crystal contacts mediated by DARPins  
 
(A) Crystal packing in the MBP-DARPin complex. The crystals belong to space group P21. One 
complex is shown in ribbon representation and colored dark blue (MBP) and green (DARPin). The 
neighbouring molecules are shown in worm representation in light blue and purple. Crystal contacts 
are mediated mainly between adjacent DARPin and MBP molecules. 
(B) Crystal contacts of AcrB molecules and the DARPin. The crystals belong to space group P212121. 
The AcrB subunits A, B, and C are colored dark blue, light blue, and gray, respectively. One of the 
two DARPins (in green) bound to the periplasmic part of AcrB mediates essential crystal contacts to 
the cytoplasmic part of a symmetry-related trimer, resulting in a different packing to AcrB crystallized 
without a DARPin. 
(C) Asymmetric unit content of the Plk-1/DARPin crystal. The two complexes are shown in ribbon 
representation and are colored gray and blue (Plk-1) and purple and green (DARPin). The N- and C-
terminal ends are labeled.  
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CHAPTER 3 
 
MULTIDRUG EFFLUX IN ESCHERICHIA COLI: THE ACRAB-TOLC SYSTEM 
65
Multidrug efflux systems are widespread in Gram-negative bacteria, although 
the contribution of many, if not most, of these to intrinsic or acquired resistance has 
not been demonstrated. Analysis of the E. coli genome has revealed the presence of 
seven RND-transporters (Table 1) [1]. Six of them have been functionally 
characterized to participate in multidrug efflux and one RND-transporter, CusA, was 
shown to confer resistance to copper. AcrF, MdtF and MdtB are not expressed at 
significant levels and seem therefore not important for the intrinsic resistance of E. 
coli as the knock-out of these did not alter the drug susceptibilities [2]. Interestingly, 
the overexpression of AcrF could suppress the hypersusceptible phenotype of acrAB 
mutants [3]. AcrD, although not associated with any gene for an MFP or an OMP, 
seems to work in complex with AcrA and TolC [4] and plays a role in efflux of 
aminoglycosides [5]. Nevertheless, as predominant pump in terms of efflux of 
clinically relevant antibiotics, AcrB is by far the best characterized of all RND 
transporters to date. An acr mutation on the chromosome that led to a 
hypersusceptible phenotype was already described in 1965 [6], but it was attributed 
for a long time to an alteration of the outer membrane permeability of the bacteria. 
The cloning of the AcrAB locus finally revealed that AcrB actually codes for a 
transporter [7]. In E. coli, AcrB is the major constitutively expressed drug efflux pump 
and works in a large multicomponent system together with two essential components 
- the first being the OMP TolC and the second the MFP-family member AcrA. 
 
Table 1: RND efflux pumps of E. coli. Adapted from [8]. 
 
Efflux system  Substrate(s) References 
Genetic context RND OMP   
acrAB AcrB TolC AC, BL, BS, CM, CV, 
EB, FA, FQ, ML, NO, 
OS, RF, SDS, TX 
[7] 
acrD AcrD  TolC AG, DC, FU, NO [5] 
acrEF (envCD) AcrF  TolC AC, BS, FQ, SDS, 
TX 
[9] 
mdtABCD (yegMNOB) MdtBC  TolC DC, NO [10, 11] 
yhiUV  MdtF  TolC CV, DC, NO, SDS [12] 
cusCFBA (ylcBCD-ybdE) CusA  CusC Copper (silver) [13] 
AC = acriflavine; AG = aminoglycosides; BL = -lactams; BS = bile salts; CM = chloramphenicol; CV = crystal 
violet; DC = deoxylcholate; EB = ethidium bromide; FA = fatty acids; FQ = fluoroquinolones; FU = fusidic acid; 
ML = macrolides, NO = novobiocin; OS = organic solvents; RF = rifampicin; SDS = sodium dodecyl sulfate; TX = 
Triton X-100. 
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3.1 TolC  
 
TolC is a multifunctional protein, being involved in the translocation of both 
small drugs and large proteins, including enzymes and toxins such as haemolysin. It 
achieves these different roles by interacting with diverse transporters such as the 
RND-transporter AcrB or the ABC-transporter HlyB. The crystal structure of TolC at 
2.1 Å resolution revealed a fold never observed before. TolC adopts a trimeric 
arrangement comprising a pore-like 40 Å -barrel domain that spans the outer 
membrane and a 100 Å periplasmic -helical barrel domain, [14] (Fig. 1A-C). The 
right-twisted -barrel domain is composed of 12 -strands in total. The left-twisted -
helical domain is formed by six pairs of antiparallel -helices that form six coiled-coils 
each containing a long (67 residues) and two shorter (23 and 34 residues) helices. A 
third equatorial mixed / domain connecting the shorter helices forms a belt around 
this helical barrel. The -barrel is constitutively open to the cell exterior but the coiled 
helices at the periplasmic end of the -helical barrel seem to close off the periplasmic 
entrance. An opening of the channel was proposed based on the small differences in 
the superhelical twist between the three inner (helices 7 and 8) and three outer 
(helices 3 and 4) coiled coils (Fig. 1D). It was suggested that an iris-like untwisting of 
the inner coils with respect to the outer coils could open the channel. In vivo and in 
vitro mutational experiments supported this hypothesis [15, 16]. Furthermore, the 
inner and outer coiled coil helices are similar in sequence, suggesting that both 
coiled-coils can adopt both conformations. 
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Fig. 1.  
3D-Structure of TolC, the OMP of the AcrAB system of E. coli (PDB ID code: 1EK9). A The 
biologically active, trimeric molecule is depicted in a ribbon diagram with the three subunits colored 
individually. B Ribbon diagram of a single subunit. The -barrel domain is colored in yellow, the -
helical barrel domain in green and the equatorial domain in red. C Topology diagram for the TolC 
monomer. D The closed and modelled open states of TolC. Adapted from [14]. 
 
3.2 AcrA 
 
The crystal structure of AcrA (residues 45 to 312 of the 397 amino acid 
residues protein) was solved at 2.7 Å resolution. Similar to the homologous MexA 
structure (see chapter 4.2) [17], the AcrA structure revealed only the core of the 
protein, namely residues 53 to 299. The remaining residues were either not in the 
construct (residues 1 to 25), removed by proteolysis (residues 26 to 44 and 313 to 
397) or not visible in the electron density. Furthermore, the AcrA construct contained 
four methionine substitutions which were constructed for MAD phase determination. 
This mutant diffracted significantly better than the wildtype protein. The introduction 
of these 4 methionine residues into the full length AcrA had functional consequences 
leading to hypersensitivity towards several substrates of the AcrAB-TolC pump while 
showing a drastic decrease in the expression level.  
 
AcrA displayed a very similar structure as MexA, most likely a consequence of 
their 62% sequence identities. AcrA is an elongated molecule consisting of three 
domains: a -barrel, a lipoyl domain and a coiled-coil -helical hairpin (Fig. 2). The -
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helical hairpin in AcrA is seven residues longer than in MexA and displays five heptad 
repeats per helix.  
 
In an attempt to define the biologically relevant oligomeric state of MFPs, the 
crystal packing was carefully analyzed. In contrast to MexA which crystallized as a 
tridecamer, AcrA crystallized as a dimer of dimers. The slightly different 
conformations of the four molecules were interpreted as conformational flexibility of 
the hinge region at the base of the -helical hairpin domain, which could have an 
influence in opening of the OMP. 
 
 
 
Fig. 2.  
3D-Structure of AcrA, the MFP of the AcrAB system of E. coli (PDB ID code: 2F1M). A The AcrA 
monomer is depicted in a ribbon diagram, with the domains colored individually. The last residues 
visible in the electron density, the three domains and the secondary structures are indicated. B The 
dimer of dimers found in the asymmetric unit of the crystal. Adapted from [17]. 
 
3.3 AcrB 
 
The crystal structure of AcrB was first determined in 2002 at 3.5 Å resolution 
and revealed the general architecture of an RND-transporter (see 1.4). AcrB consists 
of 1049 amino acids with a molecular mass of around 114 kDa. The structure 
confirmed many of the predictions regarding the functional unit of the transporter. It 
adopts a homotrimeric arrangement and comprises a transmembrane domain with 12 
membrane-spanning -helices per subunit and a large periplasmic domain. This 
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structure was followed by several structures harbouring substrates at diverse 
proposed binding sites [18, 19] suggesting a drug translocation pathway through the 
central region of the protein.  
 
However, a convincing model for the transport mechanism and the multidrug 
binding capacity of this transporter was not provided by any of these studies. 
Therefore we attempted to determine the structure of AcrB in complex with a selected 
DARPin to higher resolution which should provide new insight into the transport 
mechanism of AcrB, and presumably other members of the RND-transporter family. 
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Drug Export Pathway of Multidrug Exporter
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The multidrug exporter AcrB is the inner membrane component of the AcrAB-TolC drug efflux system in Escherichia coli
and is responsible for the resistance of this organism to a wide range of drugs. Here we describe the crystal structure of
the trimeric AcrB in complex with a designed ankyrin-repeat protein (DARPin) inhibitor at 2.5-A˚ resolution. The three
subunits of AcrB are locked in different conformations revealing distinct channels in each subunit. There seems to be
remote conformational coupling between the channel access, exit, and the putative proton-translocation site,
explaining how the proton motive force is used for drug export. Thus our structure suggests a transport pathway not
through the central pore but through the identified channels in the individual subunits, which greatly advances our
understanding of the multidrug export mechanism.
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Introduction
Drug resistance is a medical problem, ranging from cancer
cells evading chemotherapy to bacteria surviving antibiotic
treatment. Efﬂux pumps represent one class of integral
membrane transport proteins in bacteria that confer anti-
biotic resistance [1]. These proteins actively detoxify the
intracellular space by exporting drugs to the cell exterior.
AcrB of Escherichia coli is such an efﬂux pump belonging to the
subclass of resistance-nodulation-cell division transporters,
which catalyze drug export driven by proton antiport [2].
AcrB associates with the outer membrane channel TolC [3]
and the periplasmic protein AcrA [4] and allows direct and
efﬁcient transport of a wide range of toxic substances [5]. The
structures of AcrB alone [6] and of AcrB in complex with
substrates [7,8] revealed the general architecture of the
transporter. However, despite all mutational and structural
studies to date, the mechanism explaining how substrates are
transported into the extracellular media was still unclear.
The use of antibody fragments as crystallization aids for
membrane proteins has yielded a number of crystal struc-
tures [9,10]. The binding of such antibody fragments enlarges
the hydrophilic extramembranal surface of integral mem-
brane proteins, thereby providing additional surface for
crystal contacts. They can also stabilize a speciﬁc conforma-
tion supporting the crystallization process. The drawback of
the antibody fragment approach is that it is not always easy to
get an antibody fragment that recognizes and binds to a
particular conformation of a membrane protein. Further, the
selected antibody fragment might be unstable or production
might be difﬁcult. To circumvent these problems, we applied
an approach based on designed ankyrin-repeat proteins
(DARPins) as an alternative to antibody fragments. DARPins
can be selected to bind almost any given target protein with
high afﬁnity and speciﬁcity [11]. They are very stable and can
be produced as soluble proteins in large amounts by bacterial
expression. As DARPins interact with their target protein
with an exposed interaction surface, they tend to bind to
conformational epitopes rather than to peptidic ones. These
characteristics make DARPins ideal tools to help the
structural studies of membrane proteins.
Here we selected DARPins that not only bind to AcrB but
also inhibit bacterial drug export. Crystals of a selected AcrB–
DARPin complex were obtained, and the structure was
determined at 2.5-A˚ resolution. It is the ﬁrst structure of an
integral membrane protein with a selected DARPin molecule
binder. The structure reveals a previously unknown asym-
metric conformation of the efﬂux pump, in which each of the
three subunits has a unique well-deﬁned conformation. The
internal asymmetry of AcrB is underlined by the fact that
only two of the three subunits of AcrB are recognized by
DARPins in crystallo and in solution and is in contrast to the
3-fold symmetric structures reported to date [6–8]. The
structural features described here together with the enhanced
resolution allow us to deduce a pathway for drug export and a
mechanism for the coupling of substrate export with proton
import.
Results
DARPin Selection and Inhibitor Screening
DARPin binders were selected in vitro by ribosome display
using a designed ankyrin-repeat protein library [11,12]. The
selection was performed on puriﬁed and in vitro biotinylated
AcrB under native conditions. Four rounds of ribosome
display were sufﬁcient to select a pool of speciﬁc DARPins
binding to AcrB. These experiments are to our knowledge the
ﬁrst ribosome display selections performed in the presence of
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detergent to select speciﬁc binders to an integral membrane
protein.
The pool of speciﬁc binders was subjected to an in vivo
screen, based on replica plating, to identify those AcrB-
binding DARPins which lead to an inhibitory phenotype. As
AcrB is crucial for the transport of certain substrates, its
inhibition will consequently lead to accumulation of sub-
strates in the bacterial cell and consequently to cell death. We
chose Rhodamine 6G (R6G) as substrate for AcrB. The
enriched pool after four rounds of ribosome display was
cloned into an expression plasmid under the control of an
isopropyl-b-D-thiogalactopyranoside (IPTG)-inducible pro-
moter. E. coli strain XL1-blue was transformed and plated
under nonselective conditions, in absence of R6G. About
1,500 colonies were subsequently replica-plated under selec-
tive conditions, in the presence of 32 lg/ml R6G. By this
procedure, 18 single clones were identiﬁed which showed a
rhodamine-sensitive phenotype. These selected clones were
sequenced and assayed for expression. Analysis of the
sequences showed that all 18 clones were different and
unique.
The afﬁnities of the AcrB inhibiting DARPins were
analyzed by surface plasmon resonance using a BIAcore
(http://www.biacore.com) instrument. The analysis was per-
formed on AcrB-coated sensor surfaces with multiple con-
centrations of the DARPins and was evaluated with a global
kinetic ﬁt. The ﬁve inhibitors with highest afﬁnity, having
dissociation constants in the low nanomolar range (3.6 to 98.9
nM; Figure S1), were chosen for further characterization.
Clone 1108_19, which was used for cocrystallization, had a
dissociation constant KD of 28 nM.
Inhibition Efficiency of the DARPins
We rated the inhibition efﬁciencies of the identiﬁed
DARPins by spotting the clones onto selective plates with
different R6G concentrations, ranging from 2 to 64 lg/ml
(Figure 1). All inhibitors showed a signiﬁcant increase of the
sensitivity compared to cells expressing an unselected non-
binding DARPin, termed E3_5 [13]. This control also showed
that the expression of a nonbinding DARPin per se has no
inﬂuence on R6G sensitivity or bacterial growth. The acrB
gene-deletion strain KAM3 [14] causes hypersensitivity to
R6G and was used as a sensitivity control. In absence of R6G,
DARPins conferring R6G sensitivity did not inﬂuence E. coli
growth by themselves. It should be noted, however, that the
afﬁnity of the inhibitors does not always correlate with the
inhibition efﬁcacy (Figure S1). Possible factors leading to this
observation include different expression levels or different
binding sites of the DARPins on AcrB. Moreover, the exact
inhibition mechanism is not known, even for the inhibitor
1108_19 for which the structure was solved. Different
inhibition mechanisms seem plausible ranging from allosteric
inhibition of the rotary export mechanism of AcrB by the
DARPin to simply preventing the interaction with TolC or
AcrA to form the export complex.
Overall Structure of the AcrB–DARPin Complex: Loss of
the 3-Fold Symmetry
AcrB exists as a homotrimer, with each subunit containing
12 transmembrane (TM) helices and a large periplasmic part
formed by two loops between TM helices 1 and 2 and TM
helices 7 and 8. The trimer consists of three prominent
domains, the TM domain, and parallel to the membrane, the
adjacent pore domain and the TolC docking domain (Figure
2A). The TM domain encompasses a large central cavity, 35 A˚
in diameter, through the membrane which is closed toward
the central funnel formed by the TolC docking domain by
three helices provided by the PN1 subdomains of the pore
domain (Figure 2B and 2C). The export of substrates was
proposed directly through this central pore. Several struc-
tures of ligand-free AcrB and with bound substrates have
been solved at moderate resolution (between 3.5 and 3.8 A˚).
Yu et al. [7,8] reported structures of AcrB–ligand complexes
showing ligand binding to the upper wall in the central cavity
and additional substrate binding in the periplasmic domain,
compatible with mutational studies, which indicated that
discrimination between different toxic substrates occurs in
the periplasmic domain, rather than in the TM domain
[15,16]. All structures determined to date imply 3-fold
symmetry and thus the three AcrB subunits displayed the
same conformation.
To analyze the interaction and to characterize the
inhibition property of a selected DARPin, we determined
the crystal structure of one inhibitor (1108_19) in complex
with AcrB. The crystals diffracted to 2.5-A˚ resolution and
belonged to space group P212121. The structure was solved by
molecular replacement using the structure published by
Murakami et al. [6] as a search model without using the phases
of the DARPin. The results of the data collection and
reﬁnement are presented in Table 1.
The crystal structure of the AcrB–DARPin complex shows
two DARPin molecules bound basically to two subunits,
named A and B, in the homotrimeric transporter, while the
third subunit, named C, is not bound (Figure 2A and 2B).
Unlike previously determined crystal structures, there is no 3-
fold symmetry of AcrB with the DARPin molecules stabilizing
three distinct conformations of the subunits. The conforma-
tions of the DARPin-bound subunits A and B are similar to
the known symmetric structure. A superposition on Protein
Data Bank entry 1IWG [17] shows a few differences for these
Author Summary
Bacterial resistance to antibiotics is a major challenge for the current
treatment of infectious diseases. One way bacteria can escape
destruction is by pumping out administered drugs through specific
transporter proteins that span the cell membrane. We used designer
proteins that bind to and stabilize proteins of interest in order to
study the major drug efflux pump of Escherichia coli, AcrB. After
selecting for designed ankyrin repeat proteins (DARPins) that inhibit
this pump, we determined the crystal structure of a DARPin inhibitor
in complex with AcrB. We confirmed that the AcrB is split into three
subunits, each of which exhibits distinctly different conformations.
Moreover, we show that each subunit has a differently shaped
substrate transport channel; these variable channels provide unique
snapshots of the different conformations adopted by AcrB during
transport of a substrate. The structure also offers an explanation for
how substrate export is structurally coupled to simultaneous proton
import—thus significantly improving our understanding of the
mechanism of AcrB. This is the first report of the selection and co-
crystallization of a DARPin with a membrane protein, which
demonstrates the potential of DARPins not only as inhibitors but
also as tools for the structural investigation of integral membrane
proteins.
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two subunits with root-mean-square deviations of 1.72 A˚ and
1.98 A˚, respectively, for 1,033 Ca atoms, compared to 2.95 A˚
for the third subunit C. To validate in solution the 3:2 (AcrB
monomer to DARPin) stoichiometry observed in the crystal
structure, we performed sedimentation velocity experiments.
Single molecular weight species taking the detergent micelle
into consideration were observed, with molecular masses of
374 6 1.6 kDa for AcrB alone and 408 6 1.7 kDa for the
complex (Figure S2). The mass difference indicates that AcrB
in solution is bound by two DARPins, with a calculated mass
of 17.8 kDa each.
As can be seen in the crystal structure (Figure 2A and 2B),
the DARPins bind mainly to the b-sheet connecting the pore
domain with the TolC docking domain interacting, as
expected, primarily through their randomized concave sur-
face area. The interface buries a surface of around 1,000 A˚2
(see Table S1 for detailed interactions). Furthermore, each
DARPin interacts with the adjacent preceding subunit of
AcrB via one additional hydrophobic interaction involving
Leu230 of the intersubunit connecting loop as well as two
interactions involving the residues Arg263 and Lys248, again
of the preceding subunit (Table S1). Subunit C is in a
different orientation, and consequently no DARPin is bound.
Notably, the DARPins not only stabilize the asymmetric
conformation of AcrB but are also involved in direct
interactions in the crystal lattice (Figure S3), resulting in a
different crystal form P212121.
Structure Reveals Channels Leading through the
Individual Subunits
The three AcrB subunits are bound in three different
conformations, revealing three distinct channels (Figure 3).
The width of these channels is sufﬁcient for the passage of
typical AcrB substrates. In subunit A, a channel is observed,
extending from the external depression through the large
periplasmic domain reaching almost the central funnel at the
top of the protein (Figure 4A). Here the side chains of
residues Gln124, Gln125, and Tyr758 form a gate, closing the
channel and therefore preventing direct access to the central
funnel. The periplasmic channel entrance corresponds
perfectly with the periplasmic binding site indicated in the
AcrB–ligand structures of Yu et al. [8]. A similar channel,
although a little wider, is present in subunit B (Figure 4B). In
addition, the channel is open not only to the periplasm but
also to the membrane bilayer at the periphery of the TM
domain. In subunit C, the channel entrances are closed due to
movements of PC2 and PN1 (Figure 4C). In contrast to
subunits A and B, the gate to the central funnel at the top of
the periplasmic domain formed by residues Gln124, Gln125,
and Tyr758 is now open, allowing the substrate to enter the
central funnel from where it most probably reaches TolC and
is exported to the cell exterior.
Structural Rearrangements in the Putative Proton-
Translocation Site
The opening and closing of the channel entrances and the
gate is coupled to structural rearrangements in the putative
proton-translocation site in the TM domain (Figure 5A)
involving residues in the middle of the TM helix 4 (Asp407
and Asp408) and TM helix 10 (Lys940), respectively (Figure
5B). These charged residues are localized in the center of the
hydrophobic TM domain and have been shown to be essential
for the proper function of AcrB, since the mutation of these
residues leads to complete loss of drug resistance [18]. In
subunits A and B, Lys940 forms a salt bridge to the side chains
of Asp407 and Asp408, which are also involved in H-bonds
with Ser481 and Thr978 presenting the same conformation
described to date [6]. In subunit C, this salt bridge is not
formed; instead Lys940 is tilted away, forming new polar
contacts to Asn941 and Thr978.
Figure 1. Phenotype of E. coli XL1-Blue Strain Expressing the Selected Inhibitory DARPins
Six AcrB inhibitors (2907_5, 1108_5, 1108_6, 1108_9, 1108_19, and A11), one unselected nonbinding DARPin (E3_5), and an acrB knockout strain (KAM3
[14], transformed also with E3_5) were ranked for their R6G sensitivity. Induction of the DARPins results in the inhibition of AcrB, yielding an R6G-
sensitive phenotype. E. coli cells were transformed with the respective plasmid and plated under different conditions: nonselective, no R6G or no IPTG;
selective where different R6G concentrations create an environment in which inhibitory DARPins repress growth. All plates contained IPTG (except plate
no IPTG). The plates were colored with Coomassie brilliant blue for better visibility of the colonies.
doi:10.1371/journal.pbio.0050007.g001
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The conformational changes described for the putative
proton-translocation site are linked to the opening and
closing of the channel entrances and the gate described above
via rigid movements of TM helix 5 and TM helix 8 (Figure
5A). Distinct conformational differences of the polypeptide
stretch that connects the N-terminal end of TM helix 8 to PC2
can be observed in each subunit (Figure 4). The functional
importance of this connection is underlined by the fact that
each subunit displays a different conformational state of this
polypeptide stretch. In subunit A, the stretch shows a long
random coil conformation, whereas in subunit B, it adopts
partially a helical conformation but with still some random
coil conformation. In subunit C, the polypeptide segment is
in a completely a-helical conformation continuing the TM
helix 8 up to the headpiece subdomain PC2.
The loss of the interaction of Asp407, Asp408 with Lys940
in the putative site for proton-translocation, the simulta-
neous closing of the channel entrances, and the opening of
the gate are evident. This hints at a coordinated control or a
coupling of drug export and proton-translocation. The
coupling seems to occur via the polypeptide segment that
connects TM helix 8 and PC2.
Comparison of Asymmetric AcrB Structures
During the review process of this manuscript, the asym-
metric structure of AcrB was published by two other groups
[19,20]. Our experimental approach, however, differs from
theirs as we apply a new technology using DARPins as
crystallization aid. This lead to a new crystal form, P212121,
and, ﬁnally, crystals diffracting to higher resolution. Notably,
the structural comparison reveals that all three independent
structure determinations of AcrB resulted all in almost
identical structures. The root-mean-square deviations for
1,032 Ca atoms (Table S2 and Video S1) is around 1, which is
a very good correlation at the given resolutions of the
different structures (2J8S, 2.5 A˚; 2DHH, 2.8 A˚ [19]; 2GIF, 2.9 A˚
[20]). Importantly, the region where the DARPins bind shows
no signiﬁcant differences in all the structures. This clearly
demonstrates that the selected DARPins bind and stabilize an
existing conformational state and do not induce a nonnative
conformation upon binding. Murakami et al. [19] also
crystallized the protein in the presence of two substrates,
which greatly substantiates our ﬁndings. In conclusion, all
three crystal structures lead to virtually identical conclusions
Figure 2. Crystal Structure of the AcrB–DARPin Complex
(A) Ribbon diagram of the overall AcrB–DARPin complex structure viewed from the side, depicted in three different colors for each subunit: green, blue,
and yellow for A, B, and C, respectively. The DARPins are colored in red. This color code is used throughout all the figures. The locations of the three
prominent domains are indicated and the important regions are highlighted and labeled in subunit C (G, gate; ED, external depression; P, putative
proton translocation site; H, helix 8).
(B) Ribbon diagram of the overall AcrB–DARPin complex viewed from the periplasm.
(C) Ribbon diagram of the pore domain viewed as in (B). The subdomains are labeled.
All figures of the molecular models were generated with PyMOL [31].
doi:10.1371/journal.pbio.0050007.g002
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about the drug export pathway and we all proposed similar
export mechanisms.
Discussion
Cocrystallization of the membrane protein AcrB and a
DARPin inhibitor selected from a large combinatorial library
resulted in crystals that diffract to high resolution. The
signiﬁcant higher resolution of our structure compared to
the structures published to date allowed unambiguous
modeling of the side chain conformations and the interpre-
tation of structural rearrangements extending from the
putative proton-translocation sites in the center of the
membrane to the gate in the periplasmic domain. The quality
of the structure is underlined by 11 resolved detergent
molecules (Figure S4). Our work shows for the ﬁrst time the
structure of an integral membrane protein with a selected
DARPin molecule, an experimental approach that has great
potential for the structural biology of these exceedingly
difﬁcult proteins. DARPins may aid by stabilizing certain
conformations and by extending the hydrophilic surface
similar to antibody-derived protein fragments.
In contrast to the previously known R32 crystal form of
AcrB with one monomer in the asymmetric unit, in our
structure there are one AcrB trimer and two DARPins in the
asymmetric unit, and therefore there are no constraints
regarding the conformation of the individual subunits of
AcrB. Indeed, the crystal structure shows different confor-
mations for the three individual subunits and reveals
channels extending either from the periplasm and the
membrane bilayer to a gate near the central funnel at the
top of the protein or as in one subunit extending from the
gate directly into the central funnel. Moreover, we were able
to conﬁrm the 3:2 stoichiometry in solution, conﬁrming the
internal asymmetry of AcrB. We believe that the three
conformations likely present intermediates in the transport
cycle and suggest a rotary mechanism for drug transport
where the three subunits strictly alternate their conformation
in a concerted way (Figure 6). The R6G-sensitive phenotype
of cells expressing the DARPin supports this hypothesis. AcrB
may be locked by the DARPins and therefore the rotation of
the molecule is stopped. It seems unlikely that the subunits
export drugs independent of each other. If this was the case,
subunit C would still be functional, and this would be in
contrast to the observed inhibitory phenotype induced by the
DARPin. Another possibility for the inhibitory effect of the
DARPin is that either TolC or AcrA is unable to bind AcrB
Table 1. Data Collection and Refinement Statistics
Method Parameter AcrB/1108_19
Data collection Space group P212121
Unit cell parameters (A˚) a ¼ 146.18, b ¼ 157.41, c ¼ 246.04
Resolution (A˚) 35.00–2.54 (2.70–2.54)a
Completeness (%) 95.0 (79.9)
Rmerge
b 0.081 (0.321)
I/r(I) 20.75 (6.1)
Refinement Resolution 25.00–2.54 (2.70–2.54)
Number of reflections 177,557
R/Rfree (%)
c 22.9/27.0
RMS deviations
Bond lengths (A˚) 0.008
Bond angles (8) 1.3
Ramachandran plot (%)
Most favored 88.4
Allowed 10.8
aValues in parentheses are for the highest resolution shell.
bRmerge ¼
P
h
P
j j,I.h  Ih,jj/
P
h
P
jIh,j, where ,I.h is the mean intensity of symmetry-
equivalent reflections.
cR ¼ PjFobs  Fcalj/
P
Fobs. The formula for Rfree is the same as that for R, except it is
calculated with a portion of the structure factors that had not been used for refinement.
doi:10.1371/journal.pbio.0050007.t001
Figure 3. Channels in the AcrB Trimer
Stereo view of the channels leading through the periplasmic domain of AcrB. The structure of AcrB is shown as wire model and the DARPins omitted for
clarity. The channels are shown as blue surfaces and were calculated using the program CAVER (http://loschmidt.chemi.muni.cz/caver).
doi:10.1371/journal.pbio.0050007.g003
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anymore, resulting in the loss of function of this resistance-
nodulation-cell division–type transport protein.
We believe that AcrB operates through a mechanism
resembling the alternating-access mechanism which is the
substrate-translocation mechanism most commonly de-
scribed to secondary membrane transporters [21]. We
propose that substrates could enter the channel in subunit
B via the transmembranal groove at the periphery of the TM
domain or via the external depression in the periplasmic part
of the structure close to the outer leaﬂet of the membrane.
Substrate would then be speciﬁcally bound with the gate of
the channel still closed to the central funnel at the top of the
periplasmic headpiece. Upon protonation of the proton
gating residues Asp407 and/or Asp408, conformational
changes in the TM helix 8 take place, which in turn trigger
the conformational changes in the periplasmic headpiece.
The channel entrances then close through movements of
subdomains PN1 and PC2 opening the gate toward the
central funnel at the top of the headpiece, releasing the
bound substrate into the funnel, from where it could reach
TolC and ﬁnally the cell exterior.
Figure 4. The Extension of the Channels in the Individual Subunits of AcrB
The view is the same as in Figure 2A. For simplicity, the DARPins are not shown. The channels are colored in transparent blue. The potential export
pathway is represented by dashed lines. The loop forming the bottom of the periplasmic channel entrance (PE) and TM helix 8 are highlighted in red.
The gate to the central funnel formed by the residues Gln124, Gln125, and Tyr758 is shown in space filling representation for clarity.
(A) In subunit A, the channel is opened to the periplasm, while the gate is in the closed conformation. The pore domain subdomains are labeled.
(B) In subunit B, the channel displays an open conformation to the periplasm and to the membrane bilayer (CE). The gate is in a closed conformation.
(C) Subunit C displays a closed conformation of the channel entrances, while the gate is open, extending the channel to the central funnel.
doi:10.1371/journal.pbio.0050007.g004
Figure 5. Conformational Changes in the TM Region of AcrB
(A) Wire model of the superpositioned TM domains of subunit A and
subunit C viewed from the periplasmic side. Subunit B is omitted since it
displays a similar conformation as subunit A. The individual helices are
labeled.
(B) Detailed interactions of the amino acid residues in the putative
proton-translocation site viewed in the same orientation as in (A).
Residues involved in the hydrogen-bonded network (dashed lines) are
labeled. The jFo-Fcj omit electron density map (blue mesh) of Lys940 in
subunit C is contoured at 3.5 r.
doi:10.1371/journal.pbio.0050007.g005
Figure 6. Schematic Drawing of the Transport Pathway of the AcrB Efflux
Pump Suggesting a Rotary Mechanism
Proposed mechanism: Substrate may bind into the channel through the
open entrances of subunit B. Helix 8 is only weakly pronounced and
mostly random coil. Changes of the protonation state of residues of the
putative translocation site induce the formation of helix 8 and thus the
closing of the channel entrances and the simultaneous opening of the
gate, extending the channel to the central funnel at the top of the
headpiece showing the conformation of subunit C. The bound substrate
can be released into the central funnel from where it reaches TolC and
finally the cell exterior. Deprotonation takes place, leading to the
collapse of helix 8, and the channel goes back to the original
conformation (subunit A).
doi:10.1371/journal.pbio.0050007.g006
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While this model is based on the interpretation of the
structural information seen in the asymmetric structure, it
contains all features necessary for the export of substrates
and simultaneous import of protons. It is also consistent with
mutational studies available to date [8,17]. Further experi-
ments using the crystals of the complex with drug substrates
may substantiate this mechanism. In fact, similar to the
experiments performed by Murakami et al. [19], we also could
show binding of minocycline in the identiﬁed channel at 2.5-
A˚ resolution (unpublished data). The structural ﬁndings most
likely rule out the previously proposed export of substrates
directly through the central pore of the structure.
Materials and Methods
AcrB production and puriﬁcation. AcrB was overexpressed in E. coli
strain BL21 (DE3; Novagen, EMD Biosciences, http://www.
emdbiosciences.com) overnight at 30 8C using a pET28 vector
(Novagen) containing acrB with a hexahistidine-tag at the C terminus.
Cells of 1-L bacterial culture were disrupted with a French pressure
cell, and the membranes were collected and solubilized in buffer A
(20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 10 mM imidazole, 10%
glycerol), containing 1% (w/v) n-dodecyl-b-D-maltoside (DDM) (Ana-
trace, http://www.anatrace.com). Lipids and debris were removed by
ultracentrifugation at 100,000g for 1 h. The solubilized protein was
puriﬁed with afﬁnity chromatography using Ni-NTA (Qiagen, http://
www.qiagen.com), equilibrated with buffer A, containing 0.03%
DDM. The column was washed using this buffer and 50 mM imidazole,
respectively. Puriﬁed AcrB was eluted with 200 mM imidazole added
to the above buffer.
For biotinylation purposes, AcrB was eluted in 200 mM imidazole
(pH 7.5) as the only buffering agent. The protein was chemically
biotinylated using a 15 molar excess EZ-Link Sulfo-NHS-LC-Biotin
(Pierce Biotechnology, http://www.piercenet.com) for 30 min at 4 8C.
Free biotin was removed using a HiTrap Desalting column (5 ml;
Amersham Biosciences, http://www.amersham.com) equilibrated in
buffer B (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.03% [w/v] DDM).
In vitro selection by ribosome display. Four rounds of ribosome-
display selection were carried out using an N3C DARPin library
[11,12]. In vitro biotinylated AcrB was immobilized on neutravidin-
coated wells blocked with BSA. To eliminate BSA- and neutravidin-
binding library members as well as further unspeciﬁc binders, two
pre-panning steps were applied, where neutravidin, BSA, and
biotinylated maltose binding protein (MBP) [11] were present. In
the actual panning step, binders to AcrB were thus selected. The
panning procedure was performed exactly as described previously
[11], with the modiﬁcation that all buffers contained 0.03% (w/v)
DDM, to keep AcrB stable and solubilized.
In vivo selection by replica plating. The pool of speciﬁc binders was
subjected to an in vivo screen, based on replica plating, to identify
those AcrB-binding DARPins with an inhibitory phenotype. For this
purpose, the selected pool of binders was cloned into the vector pQIA
[22]. This vector carries an expression cassette for the selected
DARPins under the control of an IPTG-inducible T5 promoter.
The pool of binders was transformed into E. coli XL1-blue cells
(recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F9 proAB
lacIqZDM15 Tn10 (Tetr)]; Stratagene, http://www.stratagene.com) and
plated under nonselective conditions (ampicillin, IPTG, no R6G).
About 1,500 colonies were subsequently replica-plated under
selective conditions (ampicillin, IPTG, R6G [32 lg/ml]). By this
procedure, 18 N3C clones were identiﬁed which showed a rhod-
amine-sensitive phenotype. The characterization of these DARPins
included sequencing, expression tests, surface plasmon resonance,
MIC determination, size exclusion chromatography studies, and
cocrystallization.
Drug susceptibility assay. The susceptibility to R6G of E. coli XL1-
blue cells expressing the selected DARPins were determined by
sequential 2-fold dilutions with LB agar/glucose plates containing 0.1
mM IPTG. R6G was used at concentrations of 2, 4, 8, 16, 32, and 64 lg/
ml. Bacterial growth was examined after 24 h at 37 8C.
Surface plasmon resonance. Surface plasmon resonance was
measured using a BIAcore 3000 instrument at 20 8C. The running
buffer was buffer B. An SA chip (BIAcore) was used with 700 RU of
biotinylated AcrB immobilized. The DARPin binding was measured
at a ﬂow of 50 ll/min with 5-min buffer ﬂow, 2-min injection of AcrB-
binding DARPin in varying concentrations (2.5 nM to 60 nM), and an
off-rate measurement of 30 min with buffer ﬂow. The signal of an
uncoated reference cell was subtracted from the measurements. The
kinetic data of the interaction were evaluated using the program
BIAevaluation 3.0 (BIAcore), and global ﬁts were used to determine
KD. The possible avidity effect of the AcrB trimer was not taken into
account in the ﬁt.
Analytical ultracentrifugation. Sedimentation velocity experiments
were conducted using a Beckman ProteomeLab XL-I (http://www.
beckmancoulter.com) with an An-50 Ti analytical rotor (Beckman).
The samples were equilibrated in buffer B at a concentration of 0.42
mg/ml. All data acquired from this experiment were obtained using
the UV/Vis absorbance detection system (Perkin Elmer, http://www.
perkinelmer.com) on the ultracentrifuge at 280 nm and double sector
12-mm charcoal-ﬁlled Epon centerpieces. The experiment was
conducted at 4 8C at a speed of 40,000 rpm. The data of 300 scans
were analyzed using the LAMM equation in the program SEDFIT [23].
Crystal preparation. To obtain crystals of the AcrB–DARPin
complex, AcrB and the selected AcrB-inhibiting DARPin 1108_19
were puriﬁed separately as described [12]. A small molar excess of the
DARPin with regard to the AcrB monomer was used to prepare the
complex, followed by puriﬁcation on a Tricorn Superdex-200
(Amersham Biosciences) column equilibrated in buffer B. The peak
fractions containing AcrB in complex with the DARPin were
concentrated using a 30-kDa-cutoff concentrator (Amicon Ultra;
Millipore, http://www.millipore.com), exchanged into 10 mM HEPES
(pH 7.5), 50 mM NaCl containing 0.03% (w/v) DDM, and again
concentrated to 13 to 15 mg/ml.
Initial crystallization screening was done in 96-well, sitting drop
crystallization plates (Greiner Bio-One, http://www.greinerbioone.
com). The initial crystals were reﬁned using standard techniques.
The crystals used for data collection appeared within 4 d in 8% PEG
4000, 50 mM ADA (pH 6.5), 200 mM (NH4)2SO4 in a hanging drop
vapor diffusion experiment at 20 8C. For data collection, the crystals
were soaked in six steps for about 15 s in the mother liquid
containing 5% to 30% glycerol and ﬂash frozen into liquid propane.
Data collection, phase determination, and structure reﬁnement.
Data were collected at the Swiss Light Source beamline PX (http://sls.
web.psi.ch/view.php/about/index.html) and processed using the pro-
gram XDS [24]. The crystal belonged to space group P212121, with a
Matthews coefﬁcient VM of 3.8 A˚
3/Da, corresponding to an estimated
water content of 67.7%.
The crystal structure was solved by molecular replacement using
the program PHASER [25,26], with the structure of the AcrB
monomer (Protein Data Bank code 1IWG [6]) used as search model.
A PHASER search with the DARPin E3_5 (Protein Data Bank code
1MJO [13]) as search model did not yield a meaningful solution. The
information obtained from the conventional PHASER protocol for
the three AcrB monomers was sufﬁcient to model one DARPin
molecule into the resulting electron density with the program O [27].
The second DARPin also was positioned in O. Reﬁnement of the
structure was carried out through multiple cycles of manual
rebuilding using the program Coot [28] and reﬁnement using CNS
[29] resulting in a ﬁnal model with an R factor of 22.9 and an Rfree
factor of 27.9. The reﬁned structure of the AcrB–DARPin complex
was validated by the program PROCHECK [30]. Three-dimensional
structural ﬁgures were prepared by using PyMOL [31].
Supporting Information
Figure S1. Surface Plasmon Resonance Analysis of the AcrB–DARPin
Complexes
The binding kinetics of selected DARPins were analyzed using a
BIAcore instrument. Different concentrations of DARPin (2.5, 5, 8,
15, 25, 40, and 60 nM) were applied to a ﬂow cell with immobilized
AcrB for 2 min, followed by washing with buffer ﬂow. The global ﬁt is
indicated in the ﬁgure by black lines.
Found at doi:10.1371/journal.pbio.0050007.sg001 (64 KB DOC).
Figure S2. Sedimentation Velocity Analysis of AcrB and the AcrB–
DARPin Complex Using the LAMM Equation in the Program SEDFIT
(A) AcrB. (B) AcrB–DARPin complex.
Found at doi:10.1371/journal.pbio.0050007.sg002 (27 KB DOC).
Figure S3. Crystal Packing of AcrB–DARPin Complex Crystals
The DARPins (in red) are involved in crystal contacts and thus
account for the different space group and most likely for the high
resolution of the structure.
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Found at doi:10.1371/journal.pbio.0050007.sg003 (902 KB DOC).
Figure S4. Detergent Molecules in the Structure
The structure contains 11 n-dodecyl-b-D-maltoside (DDM) detergent
molecules underlining the quality of the structure.
Found at doi:10.1371/journal.pbio.0050007.sg004 (738 KB DOC).
Table S1. Detailed Interactions of the AcrB–DARPin Complex
Direct hydrogen bonds between AcrB and the bound DARPins
identiﬁed by the program LIGPLOT and the interface accessible
surface area calculated with the Protein-Protein Interaction Server.
Found at doi:10.1371/journal.pbio.0050007.st001 (49 KB DOC).
Table S2. Comparison of the Asymmetric AcrB Structures
Root-mean-square deviations of Ca coordinates calculated by the
program lsqman.
Found at doi:10.1371/journal.pbio.0050007.st002 (41 KB DOC).
Video S1. Comparison of the AcrB–DARPin Complex with Other
Asymmetric AcrB Structures
Superposition of the Ca atoms of the AcrB–DARPin complex (green)
with 2DHH (blue) and 2GIF (pink).
Found at doi:10.1371/journal.pbio.0050007.sv001 (3.2 MB WMV).
Accession Numbers
The atomic coordinates and structure factors of the described
complex have been deposited in the Protein Data Bank (http://www.
rcsb.org) with accession number 2J8S.
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Figure S1. Surface Plasmon Resonance Analysis of the AcrB-DARPin complexes 
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1108_19 8.7·105 2.4·10-2 28.0·10-9 32 
1108_05 1.2·106 6.5·10-2 52.3·10-9 8 
1108_06 3.4·105 3.4·10-2 98.9·10-9 16 
1108_09 1.1·106 4.1·10-3 3.6·10-9 4 
2907_05 1.8·106 4.2·10-2 23.4·10-9 32 
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Figure S2. Sedimentation Velocity Analysis of (A) AcrB and (B) the AcrB-DARPin 
Complex 
 
(A) 
 
rmsd = 0.004265  
 
 
5 10 15 20
0
0.1
0.2
0.3
0.4
0.5
sed coefficient [S]
c(
s)
 
 
MW = 374 ± 1.6 kDa  
 
 
 
 
 
 
 
 
 
 
(B) 
 
rmsd= 0.004182  
 
 
 
5 10 15 20
0
0.1
0.2
0.3
0.4
0.5
sed coefficient [S]
c(
s)
MW = 408 ± 1.7 kDa 
Chapter 3 - Multidrug Efflux in Escherichia coli: The AcrAB-TolC System
83
 
 
 
Figure S3. Crystal Packing of AcrB-DARPin Complex Crystals 
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Figure S4. Detergent Molecules in the Structure 
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CHAPTER 4 
 
MULTIDRUG EFFLUX IN PSEUDOMONAS AERUGINOSA: THE MEXAB-OPRM SYSTEM 
 
 
 
87
The opportunistic Gram-negative pathogen P. aeruginosa causes life-
threatening infections, affecting in particular immunocompromised patients and 
patients with cystic fibrosis. A well-known characteristic of P. aeruginosa is its high 
intrinsic resistance to a variety of antimicrobial agents. The low permeability of the 
outer membrane itself can not sufficiently explain this fact. Therefore, it is believed 
that the maintenance of such a high level of antibacterial resistance is largely 
attributable to the presence of multidrug efflux pumps [1]. The analysis of the 
genome sequence of P. aeruginosa has revealed the existence 13 putative RND-
transporters (Table 1) [2, 3]. One exports heavy metals (CzcA), the others are drug 
transporters. Seven of these systems have been experimentally confirmed as 
multidrug efflux systems (Mex) systems so far. The role of the other RND-systems in 
drug transport, if any, has yet to be determined.  
 
Table 1: RND efflux pumps of P. aeruginosa. Adapted from [4]. 
 
Efflux system  Substrate(s) References 
Genetic context RND OMP   
mexAB-oprM MexB OprM AC, AG, BL, 
CM, CV, EB, 
FQ, ML, NO, 
SDS, TC, TM, 
TR 
[1] 
mexCD-oprJ MexD OprJ CM, CP, FQ, 
TC, TR 
[5] 
mexEF-oprN MexF OprN CM, FQ [6] 
mexXY MexY OprM AG, ML, TC [7] 
mexGHI-opmD MexI  OpmD AC, EB, NO, 
RD, Vanadium 
[8] 
mexJK MexK OprM/OpmH EM, TC, TR [9] 
mexVW MexW OprM AC, CM, EB, 
EM, FQ, TC 
[10] 
PA3523-PA3522-opmE PA3522 OpmE ?  
PA2528-PA2527-PA2526-opmB PA2527/PA2526 OpmB ?  
PA1435-PA1436 PA1436 ? ?  
PA156-PA157-PA158 PA158 ? ?  
czcC-czcB-czcA CzcA ? Heavy metals [11] 
AC = acriflavine; AG = aminoglycoside; BL = -lactams; CM = chloramphenicol; CP = cephalosporins; CV = 
crystal violet; EB = ethidium bromide; EM = erythromycin; FQ = fluoroquinolones; ML = macrolide; NO = 
novobiocin; RD = Rhodamine; SDS = sodium dodecyl sulfate; TC = tetracycline; TM = trimethoprim; TR = 
triclosan. 
 
The MexAB-OprM system is the major responsible factor for the intrinsic 
resistance of P. aeruginosa. Acquired resistance is often associated with mutations 
in the adjacent repressor gene mexR, a phenotype also known as nalB mutants, and 
results in overexpression of this system. MexB exhibits the broadest substrate range 
of all characterized drug transporters in P. aeruginosa transporting -lactams, -
lactamase inhibitors, quinolones, macrolides, tetracyclines, chloramphenicol, 
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novobiocin, sulfonamides, trimethoprim, thiolactomycin, dyes, detergents, triclosan 
and organic solvents [4]. Like other efflux pumps, the MexAB-OprM system consists 
of an MFP-, an RND-, and an OMP-component.  
 
4.1 OprM 
 
The structure of OprM was solved at 2.56 Å resolution [12]. Although the 
protein showed only 21% amino acid identity to its functional homologue TolC the 
two structures displayed a very similar fold (Fig. 1) (see chapter 3.1). OprM also 
forms a trimer consisting of a 12-stranded -barrel domain, an -helical barrel 
domain and an equatorial domain and similar to TolC the periplasmic end of OprM is 
closed by six coiled-coils. The major structural differences between the two 
structures are exhibited by the equatorial domain and in contrast to TolC, the -
barrel is much more constricted at the cell exterior by extracellular loops connecting 
the -strands. This constriction is large enough to inhibit the passage of any 
antibiotic. These surface loops were disordered in the second trimer in the 
asymmetric unit, suggesting some flexibility for this part of the molecule. In contrast 
to TolC, OprM transports only small molecules and no proteins. Furthermore, OprM 
is fatty acid acylated at its N-terminus which could have a function in anchoring the 
protein to the outer membrane. But as with the acylated MFPs, the acylation seems 
not to be necessary for function [13].  
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Fig. 1.  
3D-Structure of OprM, the OMP of the MexAB system of P. aeruginosa (PDB ID code: 1WP1). A 
The biologically active, trimeric molecule is depicted in a ribbon diagram. One monomer is highlighted 
in blue and green. The N- and C- terminus are indicated (of two different monomers for simplicity). B 
Topology diagram for the OprM monomer. Adapted from [12]. FA = fatty acid acyl chain. 
 
4.2 MexA 
 
The structure of MexA was solved independently by two groups at 2.4 and 3.0 
Å resolution, respectively [14, 15]. The structure presented by Akama et al. resolved 
residues 46 to 297 and the one by Higgins et al. residues 52 to 282 of the 383 
residues protein. The N-terminal periplasmic signal sequence (residues 1-23) was 
either exchanged by another sequence or omitted and Cys24 was mutated to Ser to 
prevent the attachment of a fatty acid. The remaining residues were not ordered in 
the crystal. In both structures, the MexA monomer displays an elongated modular 
structure consisting of three main domains: a -barrel, a lipoyl domain and a coiled-
coil -helical hairpin (Fig. 2A). The -barrel domain contains six antiparallel -strands 
and a single -helix located at one entrance of the barrel. The lipoyl domain forms a 
-sandwich consisting of two interlocking lipoyl motifs with four -strands each. 
These two motifs are separated by the -helical hairpin. Each helix has four heptad 
repeats.  
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Whereas MexA behaves as a monomer in solution, it formed a cylinder 
composed of two twisted arcs of six and seven monomers with a tight interaction of 
the -helical hairpin domains in both crystals (Fig. 2B). All 13 copies displayed 
essentially the same conformation. This unusual oligomeric state, however, is not 
believed to be biologically relevant, as the tethering of MexA to the inner membrane 
via their lipid modified N-terminus would be impossible. 
 
 
Fig. 2.  
3D-Structure of MexA, the MFP of the MexAB system of P. aeruginosa (PDB ID code: 1T5E). A 
The MexA monomer is depicted in a ribbon diagram and colored by secondary structure. The last 
residues visible in the electron density and the three domains are indicated. B C traces of the 13 
monomers in the asymmetric unit. Each monomer is colored differently. Adapted from [15]. 
 
4.3 MexB 
 
Many studies leading to the understanding of the transport capability, energy 
needs and structural characterisation of the RND-transporter family and the whole 
tripartite systems, respectively, were actually performed rather with MexB than AcrB 
[16-18]. Surprisingly, despite the fact that a purification protocol of the protein was 
already described in 2005 [19], a crystal structure of this protein is not available yet. 
After the successful structure determination of AcrB we went one step further and 
solved the structure of the second member of the RND-transporter family, MexB. We 
further selected DARPin binders against MexB aiming for an alternative crystal form 
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which could support the observed conformational flexibility of one subunit in the 
structure of MexB alone (see chapter 4.5).   
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Abstract 
 
Three-component efflux systems play a major role in the intrinsic and acquired 
capability of Gram-negative bacteria to extrude a plethora of compounds including 
clinically relevant antibiotics. We here report the crystal structure of the Pseudomonas 
aeruginosa multidrug exporter MexB at 3.0 Å, an intensively studied member of the 
resistance-nodulation-cell division (RND) family of secondary transporters. MexB forms 
an asymmetric homotrimer where each subunit adopts a different conformation 
representing three snapshots of the transport cycle similar to the recently determined 
structures of its close homologue AcrB from Escherichia coli, the sole structurally 
characterized member of the superfamily so far. The conformation of one subunit is 
remarkably altered compared to AcrB, indicating conformational flexibility of the whole 
system. Furthermore, a molecule identified as dodecyl maltoside (DDM) bound in the 
internal multidrug binding cavity is consistent with the binding principles seen in other 
multidrug-binding proteins. As the only missing piece of the puzzle in the MexAB-OprM 
system, the X-ray structure of MexB completes the molecular picture of the major 
responsible pump mediating drug-resistance in P. aeruginosa. 
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Introduction 
Pseudomonas aeruginosa is an opportunistic human pathogen causing severe infections. Its 
intrinsic resistance to multiple clinically relevant antibiotics and its ability to acquire high-
level resistance makes this bacterium difficult to combat (1). The resistance mainly results 
from a synergy of a low-permeability outer membrane and the expression of drug efflux 
systems (2). Typically, such efflux systems consist of an energy-providing inner membrane 
protein, a channel-forming outer membrane protein (OMP) and a periplasmic membrane 
fusion protein (MFP) necessary for stabilization or maybe with a more active role in the 
transport event itself. Thereby these complexes achieve the direct extrusion of substrates 
across the two membranes of the Gram-negative bacteria. To date, several tripartite systems 
have been identified in P. aeruginosa participating in drug efflux. Among them, the MexAB-
OprM tripartite system was the first identified (3) and as major system contributing to 
intrinsic multidrug resistance in this organism is by far the best-characterized.  
 
The inner membrane component MexB belongs to the resistance-nodulation-cell division 
(RND) family of transporters, responsible for the specificity (4, 5) and for the energy of the 
transport process (6). Characteristic for the RND-transporter family, MexB transports its 
substrates using the proton electrochemical gradient and it can accommodate a very broad 
range of substrates, such as many antibiotics, biocides, dyes, organic solvents, and detergents. 
Furthermore, the transporter may also have some other export functions as in the export of 
virulence factors that are important for the colonization and infection of host cells (7). 
 
The first crystal structure of an RND-transporter, namely AcrB, was determined by X-ray 
crystallography in 2002 and revealed the general architecture of this family of proteins (8). 
Recently, three independent structures of AcrB provided novel insights into the mechanism by 
which RND-transporters work (9-11). Compared to the first structure which exhibited three-
fold symmetry, all recently determined structures displayed an overall asymmetric shape of 
the trimeric protein where each subunit adopted a different conformation, interpreted as 
consecutive snapshots of the transport process. This finally led to the proposal of a novel 
mechanism of drug transport in which each subunit cycles through the three conformations 
such that at any given time, each conformation is adopted only by one subunit. A channel 
leading through the periplasmic domain of the protein most likely forms the pathway for 
substrates, with alternate openings, in two subunits to the periplasm/outer leaflet of the inner 
membrane and in the third subunit towards the OMP. Protonation of charged residues within 
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the transmembrane region, most probably induce the opening and closing of the channel 
entrance and exit via conformational changes in a polypeptide stretch connecting the 
transmembrane and periplasmic domain. Importantly, further studies showed that the 
asymmetry does exist not only in the crystal structure, but also in vivo and in solution (11, 
12).  
 
MexB is highly homologous to its E. coli counterpart AcrB (69.8% identity and 83.2% 
similarity in a sequence of 1046 amino acid residues). Intriguingly, despite their high degree 
of homology it is not possible to interchange the two components with regard to their 
interaction partners without loosing activity (4, 13) even though their cognate OMPs OprM 
and TolC both are multispecific per se, working with multiple RND transporters (14) or in the 
case of TolC even with members of the ATP-binding cassette (ABC)- or of the major 
facilitator (MF)-superfamily. In addition, AcrA was reported to function with several RNDs 
(5). 
 
Crystal structures have now been reported for the tripartite efflux pump components MexA 
(15, 16) and OprM (17) and for all three proteins of the homologous E. coli AcrAB-TolC 
system (8, 18, 19). In this study, we have determined the X-ray structure of the missing part 
MexB at 3.0 Å resolution. The structure confirms the asymmetric fold observed for AcrB 
recently but also shows altered relative orientations of the subunits, particularly in the subunit 
whose role in the transport process remained somewhat unclear. Furthermore, a bound 
detergent molecule in the periplasmic domain of one subunit supports the idea of a large 
multisite binding cavity with different residues involved in binding different substrates. The 
completion of the atomic resolution model of the MexAB-OprM drug export system, allows 
detailed comparison with the already fully resolved E. coli AcrAB-TolC system concerning 
the specificity of the respective MFPs and OMPs in the future. 
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Results 
Overall structure of MexB. P. aeruginosa MexB was overexpressed in E. coli, purified from 
the membrane fraction and crystals belonging to space group P1 were grown. The structure 
was solved at 3.0 Å resolution by molecular replacement using the homologous asymmetric 
AcrB structure as search model (Table 1). The asymmetric unit contained two almost 
identical trimers (chains ABC and chains DEF) with a root-mean-square deviation (rmsd) of 
the superposition of mainchain traces of the two molecules of 0.1 Å. The final model was 
refined to R factors of R = 24.3 % and Rfree = 28.7 % applying two-fold non-crystallographic 
symmetry restraints for each chain. Small breaks in the electron density were observed and 
not included in the final structure: residues 1-3, 500-511 (loop between TM6 and the 
cytoplasmic horizontal helix), and 673-677 (loop connecting PC1 and PC2) in chain A; 253-
261 (loop in the DN domain at the periplasmic end of the protein), 500-511, and 670-675 in 
chain D; 669-680, and 990-995 (loop connecting TM11 and TM12) in chain E. 
 
The global structure of MexB is similar to that of AcrB (8), which is not surprising given their 
high homology (Fig. S1). Like AcrB, MexB forms a trimer consisting of three subunits (Fig. 
1). Each monomer exhibits a complex topology, consisting of 12 transmembrane -helices 
(TM) (TM 1-12) and an extensive periplasmic domain, formed by two long loops between 
TM1 and TM2, and TM7 and TM8, respectively. This periplasmic domain folds into six 
subdomains: PN1, PN2, PC1 and PC2 building the pore domain, and DN and DC building the 
docking domain to the OMP. The DN subdomain exhibits an elongated -sheet which 
protrudes into the next subunit thereby interlocking the subunits and stabilizing the trimer. In 
the transmembrane region, a pseudo-twofold symmetry is observed, with TM1-7 related to 
TM8-12. TM4 and TM10 are surrounded by the other transmembrane helices and harbor 
well-conserved charged residues, among them Asp-407, Asp-408 (TM4) and Lys-939 (940 in 
AcrB) (TM10) which probably mediate proton translocation and have been shown to be 
indispensable for the proper function of the protein, since the mutation of these residues leads 
to a complete loss of drug resistance (20). MexB contains 1046 amino acids compared to 
1049 amino acids of AcrB and has two internal amino-acid residue deletions at positions 711 
(located in a loop in PC2) and at positions 955 (located in the cytoplasmic loop connecting 
TM10 and 11) of the AcrB sequence, respectively. 
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Comparison with the asymmetric AcrB structure. Close structural relationship is observed 
between P. aeruginosa MexB and E. coli AcrB. The overall superposition of MexB and a 
recently determined asymmetric AcrB structure (11) results in an rmsd for 2990 C positions 
of 1.4 Å. Figure 2 shows a comparison of MexB superimposed with the homologous structure 
of AcrB. As the transmembrane part is responsible for the proton translocation and is likely to 
be similar in all RND-family transporters we analyzed the differences between MexB and 
AcrB based on superpositions of the transmembrane domains. Indeed, this region is very well 
conserved in sequence (Fig. S1). Strikingly, almost all residues in the two central TMs - TM4 
and TM10 - are conserved between MexB and AcrB, including the two aspartates and the 
lysin in the putative proton-translocation site (Fig. S2). In both MexB and AcrB, Lys-939 
(940 in AcrB) of TM10 is engaged in a salt-bridge interaction with aspartate residues of TM4 
(Asp-407 or Asp-408) in subunits A and B (Fig. 2). In subunit C however, the lysin is tilted 
towards Thr-976 (978 in AcrB) of TM11. This movement implicates a rigid body shift of 
TM5 towards TM4 and TM10 and conformational changes in TM8. The N-terminal end of 
this helix which connects the transmembrane with the PC2 domain adopts different 
conformations in the subunits and is believed to be the trigger for the large conformational 
changes observed in the pore domains that finally lead to the export of substrates (Fig. 2). 
This stretch varies in AcrB from a random coil conformation with only partially defined 
electron density in subunit A to a fully -helical conformation in subunit C. Surprisingly, in 
MexB, the conformation of TM8 in subunit B resembles more the conformation in subunit C, 
in which it is fully helical. 
 
Inspection of the MexB and AcrB structures reveals non-continuous channels located in the 
periplasmic domain reaching halfway from the periplasm to a large cavity formed by the four 
pore domain subdomains or from this cavity to the OMP docking domain at the periplasmic 
tip of the protein (Fig. 3). The channels are large enough to accommodate the common 
substrates proposed to be transported by these transporters. As observed in the asymmetric 
AcrB structures, conformation B exhibits a channel open to the periplasm and could probably 
capture the substrates from the periplasm whereas the channel in conformation C opens 
towards the TolC protein allowing substrates to be released. These two subunits are oriented 
very similar compared to the AcrB structure (rmsd of 1.0 Å each) (Fig. 2). The portal from 
the membrane bilayer leading to the channel of subunit B found in AcrB is not observed in 
MexB, most likely due to a more helical conformation of the N-terminal part of TM 8 as 
mentioned before which leads to a closure of this entrance. The most striking difference 
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between MexB and AcrB however, is the conformation of subunit A (rmsd of 1.6 Å). Subunit 
A shows motions particularly in TM 6-12 and remarkable shifts occur in the pore domain, 
most notably of the PC2 subdomain. Subdomain PC2 is significantly shifted towards the 
transmembrane domain and towards PC1. These conformational shift result in a closure of the 
entrance formed by the PC domains (Fig. 2). Therefore, there is neither a channel entrance 
nor a channel exit observed in subunit A of the MexB structure (Fig. 3A). In AcrB, an 
opening is present between PC2 and PC1 which extends to the proposed binding cavity 
similar to the conformation seen in subunit B (Fig. 3B).  
 
The structures of the docking domains of MexB and AcrB, to which the corresponding OMPs 
have been shown to associate, are very similar, each consisting of two subdomains. One of the 
two subdomains forms a long protruding loop that inserts into the docking domain of the 
neighbouring subunit. Since OprM and TolC are not interchangeable between the MexAB and 
AcrAB system (4), this finding is somewhat surprising. The high specificity seems therefore 
more likely to rely on the MFP. 
 
Substrate binding by multidrug transporters. The structure presented here was solved 
using crystals grown in the presence of the nonionic detergent DDM to keep the membrane 
protein in solution. Detergents are known to be transported by multidrug transporters (21). 
Unexpectedly, positive electron density is visible within one of the binding cavities in the 
MexB trimer (Fig. 2 and Fig. 4A). Consistent with the previous determined AcrB/substrate 
complex structures (9), the density is visible only in one of the three subunits of the trimer, 
namely the binding subunit B. We interpreted the density as two maltoside rings belonging to 
a DDM molecule cocrystallizing with the transporter and placed the maltoside part in an 
orientation that fits the density. The electron density could be observed in both trimers in the 
asymmetric unit albeit with slightly different occupancy.  
 
The maltoside binds in a voluminous binding cavity created by the -sheets of the pore 
domain to a region rich in polar amino-acid residues (Fig. 4A). Residues in close proximity 
(<4 Å) are Val-47, Ser-48, and Gln-125 of PN1; Val-177, Gly-179, and Ser-180 of PN2; and 
Gln-273, and Arg-620 of PC1. These residues interact with the substrate presumably via 
hydrogen-bonding and van der Waals interactions. Not surprisingly, the C12-carbohydrate tail 
was not resolved, presumably because of high mobility. This behaviour can be observed for 
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most of the three ordered detergents bound to the transmembrane helices of the protein as 
well.  
 
The usage of different sets of residues for binding of structurally diverse substrates was 
demonstrated earlier in structures of the transcription repressor QacR harboring various 
cationic lipophilic drugs which explained the difference to substrate specific binding (22). The 
observed multisite binding seems equally valid for multidrug transporters. The binding site of 
the DDM bound to MexB corresponds to the minocycline and doxorubicin binding sites of 
AcrB (Fig. 4A). There, the minocycline is bound to residues of the PC1 and PC2 subdomains. 
The D-ring is wedged between Ile-277, Phe-615 and Phe-178. Asn-274 is tilted against the 
drug to form a hydrogen bond with the 12a-hydroxy group (unpublished results). Together, 
despite the chemical differences of the three substrates, they all bind in the binding cavity of 
the pore domain using a different but overlapping set of residues. The nature of this binding 
cavity seems to be conserved among the two homologs, exhibiting many polar residues at the 
distal end and more aromatic residues at the proximal end.  
 
The substrate specificities of the two efflux pumps is very similar when expressed in the same 
organism, e.g. E. coli (4). Nevertheless, we were not able to obtain good quality MexB 
crystals in presence of minocycline to date and likewise AcrB crystals harboring DDM. This 
fact raises the question about the structural features that underlie this difference. The answer 
to this question is not yet clear, but one of the most obvious possibilities would be differences 
within the substrate-binding sites. But the size of the binding cavity (Fig. 2B) as well as the 
amino acids lining it is not dramatically different in the two transporters. In MexB, the 
electrostatic surface potential of the binding cavity seems to be slightly more positive due to 
two exposed arginine residues (Fig. 4B).  However, it is hard to rationalize for these subtle 
differences, if they are important for determining the substrate specificity of the two 
transporters and future mutagenesis experiments will be required to uncover the structural 
features governing the substrate specificity of RND-family members. 
 
Crystal packing. The reason for the large conformational differences in subunit A is unclear. 
The most obvious reason, however, could be the arrangement of the MexB molecules in the 
crystal (Fig. S3). The two trimers of MexB in the asymmetric unit of the crystal pack together 
in a head-to-head manner involving the periplasmic part heavily. Notably, the two trimers 
associate through extensive contacts involving mainly the PC2 subdomain of subunit A. 
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Approximately 700 Å2 of surface area per molecule is buried at this interface. Thus, the 
observed altered conformation of subunit A could simply be a result of the crystal contact. 
However, there is evidence that the differences are functionally significant. First, similar 
crystal contacts occur between subunit B of a symmetry-related molecule and subunits B (E) 
and C (F) of the second molecule in the asymmetric unit which have no effect on the 
conformation (buried surface area around 450 Å2). Second, there was also a triclinic P1 
crystal form reported for AcrB where the molecules also pack head-to-head with their 
periplasmic part but with a different pore-pore domain interaction (10). Finally, the smallest 
sequence conservation between the transporters is seen in the PC1 and PC2 domains (Fig. 
S2), suggesting that the difference of these domains could be an intrinsic property of MexB 
and thus functionally important. Therefore, it is likely that the observed conformation of 
subunit A of MexB represents another naturally occurring alternative state of subunit A and 
crystal-packing effects are not likely to be responsible for the structural differences. 
 
Discussion. In this study, we have solved the 3.0 Å crystal structure of MexB from P. 
aeruginosa. This trimeric protein is part of the multicomponent pump MexAB-OprM that 
confers P. aeruginosa resistance to several dyes, detergents, and clinical relevant antibiotics. 
As expected, MexB shares the same overall fold as its close homologue AcrB. Interestingly, 
MexB adopts an asymmetric conformation where each subunit adopts a slightly different 
conformation therefore confirming the asymmetric conformation of the RND-transport 
proteins and it supports the transport model derived from the AcrB structures. 
 
Although the overall arrangement of MexB and AcrB is very similar, a prominent difference 
is seen in the pore domain of subunit A. The non-continuous channels identified clearly assign 
the binding and extrusion conformation to the conformation seen in subunit B and C, 
respectively. It is therefore suggested that subunit A presents an intermediate conformational 
state between the extrusion and binding of the substrates. Compared to AcrB, the positions of 
the pore domain subdomains of this subunit are clearly altered, with shifts particularly of the 
PC2 subdomain. This shift results in a closure of the periplasmic portal in this subunit and 
therefore no channel was found in this subunit. One might speculate that this conformation 
might represent a state in between, in which a substrate is fully captured, since two detected 
channels in a trimer per se do not unambiguously determine the direction of the rotation. But 
as we do not see a substrate bound in this subunit and we do so in subunit B we exclude this 
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possibility. The progression of a subunit through the three individual conformations is 
therefore rather ABC than ACB.  
 
The flexible nature of subunit A in these structures could probably also be due to the absence 
of the interacting partners (MFPs and OMPs). It is known that RND-transporters interact with 
their cognate MFP components most probably via the pore domain. A chimeric analysis of 
MexB and AcrB indicated that residues 589-612 are involved in MFP specificity (4). 
Consistently, a study identified the nearby mutation T578I in MexB which compromised the 
transporters contribution to antibiotic resistance most likely by impairing its interaction with 
MexA (23). These residues are all located in the PC1 subdomain. Therefore, the structural 
flexibility seen in the pore domain may be functional important and could have impact on the 
tripartite complex association. The reason for the high specificity of the individual pump 
components remains uncertain, but the specificity seems to reflect rather only subtle changes 
of the assembly interaction surfaces than large structural variations. 
 
The DDM molecule bound in subunit B together with the recently solved AcrB/substrate 
structures and the structural studies on multidrug-binding regulatory proteins expanded the 
knowledge of the capability to accommodate numerous structurally diverse compounds. The 
general properties of a multisite binding cavity seem to reiterate. All these protein/substrate 
complexes possess a large drug-binding cavity rich in polar and aromatic residues which 
provide several partially overlapping binding sites. The binding mode of the maltoside group 
of the DDM is reminiscent of the situation in the binding of maltose in the E. coli maltose 
transporter MalFGK2, where the binding involves mainly aspargines and serines which form 
hydrogen bonds to some hydroxy groups of the maltose (24). But no aromatic residue 
stacking was observed in MexB maybe indicating a weaker binding and less specificity and 
therefore reflecting the fundamental differences of specific versus multidrug transporter. 
 
Taken together, the observation that both AcrB and MexB adopt an asymmetric conformation 
suggests that bacterial RND-transporters share a common mechanism of coupling proton 
transport to substrate translocation. Furthermore, the mechanistic mobility of the system is 
reflected in the conformational flexibility of the individual subunits.  
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Materials and Methods 
Protein preparation. MexB, amplified from P. aeruginosa strain PAO1 genomic DNA 
(ATCC 47085) using PCR, was cloned into a pET28 vector using NdeI and XhoI restriction 
sites and the protein was expressed with a C-terminal hexahistidine-tag in E. coli strain C43 
(DE3; Novagen, EMD Biosciences). Bacteria were grown to an absorbance at 600 nm of 0.8 
in the presence of 50 mg l-1 kanamycin at 37 °C, and induced with 1 mM isopropyl- -d-
thiogalactopyranoside for 4 hours at 30 °C. Cells were centrifuged and lysed by French press 
in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, DNase I, 1 mM phenylmethyl sulphonyl fluoride 
(PMSF) and complete protease inhibitor cocktail. The membranes were collected for 1 hours 
at 100,000g  and solubilized in buffer A 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM 
imidazole, 1 mM PMSF, 10 % glycerol containing 1 % (w/v) n-dodecyl- -D-maltoside 
(DDM) (Anatrace,  D310LA Anagrade) for 2 h at 4 °C. The solubilized protein was 
centrifuged for 1 hour at 100,000g and the supernatant loaded onto a Ni-NTA affinity column 
(Qiagen) equilibrated with buffer A containing 0.03% DDM. The column was washed using 
this buffer and 30 mM imidazole, respectively, and the desired protein was eluted with 
200 mM imidazole.  
 
Crystal preparation. To obtain crystals of MexB, the protein was concentrated and further 
purified on a Tricorn Superdex 200 size exclusion column (Amersham Biosciences) 
equilibrated in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 % glycerol containing 0.03 % 
(w/v) DDM. The peak corresponding to the MexB trimer was concentrated, exchanged into 
10 mM HEPES pH 7.5, 50 mM NaCl buffer containing 0.03 % (w/v) DDM, and finally 
concentrated to 20-25 mg ml-1. 
 
Initial crystallization screening was done in 96-well, sitting drop crystallization plates 
(Greiner Bio-One). The crystal used for data collection appeared within 20 d in 33% PEG400, 
50 mM Na-Acetate pH 4.5, 230 mM NaCl in a sitting drop vapor diffusion experiment at 
20°C. For cryo protection, the crystals were soaked in two steps in the mother liquor 
containing 35% PEG400 and flash frozen in liquid nitrogen. 
 
Structure determination. Data were collected at the Swiss Light Source beamline PX on a 
PILATUS detector (Dectris). The data were indexed, integrated and scaled with XDS. The 
crystal belonged to space group P1, with a Matthews coefficient of 3.65 Å3/Da, corresponding 
to an estimated solvent content of 66.0%. 
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 The crystal structure was solved by molecular replacement with PHASER(25), using the 
asymmetric crystal structure of AcrB (Protein Data Bank code 2J8S) as a search model. 
Refinement of the structure was carried out through multiple cycles of manual adjustments 
and rebuilding using COOT (26) and refinement using PHENIX (27), resulting in a final 
model with an R factor of 24.3 and an R free factor of 28.7%. 
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Table 1. Data collection and refinement statistics. 
  
Data collection and processing 
Wavelength, Å 1.0000  
Space group P1 
Unit cell parameters, Å a = 125.05, b = 134.58, c = 151.02  
  = 86.99,  = 69.70,  = 88.16 
Resolution, Å 50.00-3.0 (3.1-3.0)a 
Total reflections 419193 
Unique reflections 176904 (15057) 
Completeness, % 95.7 (87.0) 
Rsym 0.041 (0.70) 
I/I) 15.26 (1.73) 
Refinement  
Resolution, Å 50-3.0 
R/R free, %b 24.3/28.7  
No. atoms 46578 
No. of detergent molecules  8 
B-factors 88.33  
rms deviations  
    Bond lengths (Å) 0.004 
    Bond angles (º) 0.802 
Ramachandran plot (%)  
Most favored 83.3 
Allowed 16.1 
 
aValues in parentheses are for the highest resolution shell. 
bR =  | Fobs – Fcal | / Fobs.  The formula for Rfree is the same as that for R, except it is calculated with a portion of the structure
factors that had not been used for refinement. 
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Figure 1 
 
 
 
 
Fig. 1. Structure and architecture of MexB. 
Ribbon diagram of the overall MexB trimer viewed in the membrane plane. The locations of the three 
prominent domains and the approximate position of the inner membrane are indicated. One monomer 
is colored according to its subdomains, with subdomains labeled and -helices numbered. The 
common terms for the naming of the three subunits are listed (9-11). All figures of the molecular 
models were generated with PyMol (www.pymol.org). 
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Figure 2 
 
 
 
 
Fig. 2. Comparison of MexB and AcrB structures. 
The MexB trimer is superimposed with the AcrB trimer (PDB ID code 2J8S) based on their 
transmembrane helices. For clarity, the subunits are individually represented in the same orientation. 
Also shown is the Fo-Fc electron density (contoured at 2.5) observed in one of the binding cavities of 
the trimer, as purple mesh. The right panel shows a close-up view of the structural differences 
occurring in the pore domain. The lower panel shows a close-up view of the TM domains illustrating 
the side chain conformations in the putative proton translocation site.  
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Figure 3 
 
 
 
 
Fig. 3. Stereo view of the channels leading to the drug binding cavity.  
(A) The channels detected in MexB are shown as blue surfaces. The subunits are individually colored: 
green (A), blue (B), and cyan (C). No channel can be observed in subunit A due to the conformational 
changes observed for the PC2 domain. The channels were calculated using the program CAVER 
(http://loschmidt.chemi.muni.cz/caver). 
(B) Channels detected in AcrB (PDB ID code: 2J8S). The subunits are individually colored: yellow 
(A), orange (B), and red (C). 
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Figure 4 
 
 
 
 
Fig. 4. Multisite binding pocket of RND-transporters. 
(A) Stereo view of the binding cavity with the Fo-Fc map contoured at 2.5. Minocycline and 
doxorubicine binding sites in AcrB are shown as yellow and grey sticks, respectively. The view is as 
for the individual subunits in Fig. 2 with PC subdomains omitted for clarity.  
(B) Comparison of the electrostatic surface potential of the binding pockets of MexB and AcrB 
(calculated with APBS). The upper panel has the same orientation as Fig. 4A. The view in the lower 
panel is from the PN1 and PC2 domains. The surface is colored blue for potentials > 10 kT/e and red 
for potentials < -10 kT/e. DDM and minocycline are shown as green and yellow sticks, respectively. 
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4.6 Selecting DARPins for the structural analysis of RND-
transporters 
 
Gaby Sennhauser, Markus G. Grütter 
 
Among the five known superfamilies of multidrug transporters, the resistance-
nodulation-division (RND) family is especially effective in generating antibiotic 
resistance in Gram-negative bacteria [1]. Within a species there are normally multiple 
genes encoding RND transporters and these proteins typically share a high degree of 
sequence homology. Escherichia coli AcrB and Pseudomonas aeruginosa MexB are 
constitutively expressed and mainly responsible for the intrinsic resistance to a wide 
variety of substances in these bacteria. The function of other close homologues such 
as AcrD and AcrF from E. coli (66% and 77% identity to AcrB, respectively) is less 
characterized since the investigation is more complicated. The substrates transported 
by these homologous are often overlapping and the range is not as broad. AcrD is 
believed to transport aminoglycosides since its deletion decreased the MIC of such 
compounds and lead to the accumulation of radioactive aminoglycosides [2]. The 
function of AcrF is more obscure since its deletion did not alter the drug-susceptibility 
of wild-type E. coli [3]. A great deal of research is being undertaken to understand the 
precise mechanisms of these RND transporters and how specificity for different drugs 
is achieved. The key to understand how these pumps work involves the 
determination of the structures of several representative proteins to atomic resolution. 
 
After the successful structure determination of AcrB in complex with a 
DARPin, the aim of this work was to select specific DARPin binders to close 
homologs of it. These binders could then facilitate the crystallization of these proteins 
in a similar way as with AcrB. 
 
The RND transporters AcrD and AcrF were cloned, expressed and purified in 
a similar way as MexB (see chapter 4.5). All proteins carried a Hexahistidine-Tag at 
their C-terminus and could be efficiently purified in presence of DDM via Immobilized 
Metal Affinity Chromatography (IMAC). Size exclusion chromatography was used as 
polishing step in purification and to roughly assess the oligomeric behaviour of the 
proteins (Fig. 1). Whereas MexB and AcrF showed only a small tendency to 
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aggregate and eluted predominantly as a symmetric peak in SEC with a molecular 
weight corresponding to a trimer, we observed a significant percentage of other 
oligomeric states for AcrD (monomer or dimer). For immobilization on streptavidin 
coated plates, the proteins were chemically biotinylated following the procedure for 
AcrB [4]. 
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Fig. 1.  
SEC profiles of all investigated RND transporters. Recombinant proteins from 0.5l E. coli culture 
were purified and applied to a Tricorn Superdex 200 column. 
 
Four rounds of ribosome display were carried out against biotinylated MexB, 
AcrD and AcrF in the presence of 0.03% DDM using an N2C DARPin library (Fig. 2) 
[4]. Two prepanning steps against maltose binding protein were included in all rounds 
and in the last round the washing step was extended to two hours.  
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 MexB AcrD  
MBP MexB  AcrD 
AcrF  
MBP AcrFMBP 
 
Fig. 2.  
Fourth round of ribosome display against three AcrB homologs. The round was done in duplicates 
and the DNA was analyzed after reverse-transcription PCR. The binding was tested against the target 
protein (first two lines) and background binding against maltose binding protein (second two lines). 
 
The pools obtained were then cloned into the pQE30 vector (Qiagen). To test 
if the crude extract ELISA protocol still works in the presence of detergent, a test 
assay was performed using the AcrB binder which lead to the crystal structure and an 
old DARPin pool generated against AcrB [4] as controls. Then the newly generetated 
pools against the homologs were analyzed (data not shown). The binders giving the 
highest signal to background ratio were sequenced, purified and further analyzed by 
competition ELISA (data not shown). 96 clones per target were analyzed in a crude 
extract ELISA. 6 binders for AcrB, 5 for MexB, 5 for AcrF and none for AcrD showed 
a specific recognition in a competition ELISA (Fig. 3). These DARPin binders were 
able to form a stable complex also during size exclusion chromatography. The kinetic 
constants of the MexB binders were further determined by Biacore experiments and 
showed that all binders possess dissociation constants in the low nanomolar range 
(Fig. 4). For the AcrF binders Biacore measurements were not possible due to a 
severe decay of baseline signal over time. This behaviour was also observed for 
MexB albeit to a much lesser extend. This problems could have been due to an 
improper immobilization technique or instability of the proteins.  
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 AcrB binders 
 
N3C MRGSHHHHHHGSDLGKKLLEAARAGQDDEVRILMANGADVNAXDXXGXTPLHLAAXXGHLEIVEVLLKXGADVNAX 
110819 .........................R................A.VV.W.......YW...........N......Y 
3A ..........................................R.FT.W.......HF...........N......K 
3C ..........................................S.HV.W.......YF...........N......D 
9E ..........................................R.II.W.......YF...........H......E 
12E ..........................................R.II.W.......YF...........H......E 
5B ..........................................F.FT.W.......YF......V....Y......T 
7C ..........................................N.YS.K.......RR...........H......I 
 
 DXXGXTPLHLAAXXGHLEIVEVLLKXGADVNAXDXXGXTPLHLAAXXGHLEIVEVLLKXGADVNAQ 
 .TL.S.......HF...........N......K.DN.I.......NR...........Y....... 
 .SL.V.......RR...........N......S.SH.F.......KR...........N....... 
 .SL.T.......DR...........N......N.HN.F.......NI...........H....... 
 .TL.S.L.....HT...........H......M.SN.H.......RL...........Y....... 
 .TL.S.L.....HT...........H......M.SN.H.......RL...........Y.....T. 
 .TI.Y.......QK...........N......N.HN.F.......NI...........Y.V..... 
 .NW.Y.......YW...........H......L.KI.N.......DC...........H....... 
 
 DKFGKTAFDISIDNGNEDLAEILQKLN** 
 ............N..............** 
 ...........................** 
 ...............S...........** 
 ...........................** 
 ...........................** 
 ...........................** 
 ...........................** 
 
MexB binders 
 
N2C MRGSHHHHHHGSDLGKKLLEAARAGQDDEVRILMANGADVNAXDXXGXTPLHLAAXXGHLEIVEVLLKXGADVNAX 
12E ..........................................I.HN.M.......YR...........Y......W 
8F ..................................V.......I.HN.M.......YR...........Y...I..W 
2C ...................KT.....................T.FS.I.R.....SK...........Y......Q 
7B ............N.............................I.FK.N.......VK...........N.....VQ 
6E ..........................................I.WN.S.......LR...........N......A 
  
DXXGXTPLHLAAXXGHLEIVEVLLKXGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN** 
 .IW.A.......HS.....F.....H..................................** 
 .IW.A.......YT...........H..................................** 
 .FF.L.......SN...........N..................................** 
 .FY.W.......TW...........Y..................................** 
 .FY.W.......TF...........N..................................** 
 
AcrF binders 
 
N2C MRGSHHHHHHGSDLGKKLLEAARAGQDDEVRILMANGADVNAXDXXGXTPLHLAAXXGHLEIVEVLLKXGADVNAX 
5E ..........................................K.SW.Q.......TY...........H......D 
6C ..........................................N.DY.Q......TTY...K.......Y......S 
12B ....................T.....................N.DY.Q......TTY...........YS.....S 
9D ..........................................N.DY.Q......TTY...........Y......S 
9A ..........................................D.NH.F.......HY...........Y.....DH 
 
DXXGXTPLHLAAXXGHLEIVEVLLKXGADVNAQDKFGKTAFDISIDNGNEDLAEILQKLN**
 .ME.F.......IT...........Y..................................** 
 .QM.F.......IL...........Y..................................** 
 .QM.F.......IL...........Y..................................** 
 .QM.F.......HT.R.........Y.........I........................** 
 .LI.W.......YL.R.........Y..............L...............RN* 
 
 
 
 
 
 
 
 
 
 
Fig. 3.  
Sequences of DARPins binding to RND transporters. 
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Fig. 4.  
The association and dissociation rate constants were determined using SPR. For the MexB binding 
DARPin 12E, a dissociation constant of 1.2 nM was calculated.  
 
Finally, we found that the selected DARPin molecules were extremely specific. 
Despite the close homology all DARPins specifically recognized only the target 
protein against which they were selected (Fig. 5). 
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Fig. 5.  
Specificity of the DARPins (each 50 nM; control with no DARPin) with immobilized MexB, AcrB, AcrD, 
AcrF and neutravidin is shown. A MexB binders and the AcrB binder 110819. B AcrF binders and the 
AcrB binder 110819.  
 
All RND-transporter-specific DARPins in complex with their corresponding 
target were subjected to crystallization. No crystals were obtained for AcrF/DARPin 
complexes. Among the five MexB binders, one binder, termed 12E yielded crystals. 
Indeed the conditions leading finally to the MexB structure were originally obtained in 
presence of 12E in the protein solution. However, it turned out that the complex must 
0
sTime
B
OD405OD405 
A 
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have dissociated under the specific crystallization condition since no density could be 
seen for a bound DARPin.  
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